<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767848</article-id>
    <article-id pub-id-type="pmid">37956338</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad1060</article-id>
    <article-id pub-id-type="publisher-id">gkad1060</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DriverDBv4: a multi-omics integration database for cancer driver gene research</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Chia-Hsin</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lai</surname>
          <given-names>Yo-Liang</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shen</surname>
          <given-names>Pei-Chun</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Hsiu-Cheng</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tsai</surname>
          <given-names>Meng-Hsin</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yu-De</given-names>
        </name>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Department of Urology, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lin</surname>
          <given-names>Wen-Jen</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>School of Medicine, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Fang-Hsin</given-names>
        </name>
        <aff><institution>Institute of Nuclear Engineering and Science, National Tsing Hua University</institution>, <addr-line>Hsinchu 300044</addr-line>, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Chia-Yang</given-names>
        </name>
        <aff><institution>Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University</institution>, Kaohsiung 80708, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Shu-Chi</given-names>
        </name>
        <aff><institution>Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University</institution>, Kaohsiung 80708, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hung</surname>
          <given-names>Mien-Chie</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Institute of Biochemistry and Molecular Biology, China Medical University</institution>, <addr-line>Taichung 404328</addr-line>, <country country="TW">Taiwan</country></aff>
        <aff><institution>Molecular Medicine Center, China Medical University Hospital, China Medical University</institution>, <addr-line>Taichung 404328</addr-line>, <country country="TW">Taiwan</country></aff>
        <aff><institution>Department of Biotechnology, Asia University</institution>, <addr-line>Taichung 413305</addr-line>, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1229-4857</contrib-id>
        <name>
          <surname>Cheng</surname>
          <given-names>Wei-Chung</given-names>
        </name>
        <!--cwc0702@gmail.com-->
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>The Ph.D. program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +886 4 2205 2121 (Ext 7820); Fax: +886 4 2233 3496; Email: <email>cwc0702@gmail.com</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-11-13">
      <day>13</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1246</fpage>
    <lpage>D1252</lpage>
    <history>
      <date date-type="accepted">
        <day>25</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad1060.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Advancements in high-throughput technology offer researchers an extensive range of multi-omics data that provide deep insights into the complex landscape of cancer biology. However, traditional statistical models and databases are inadequate to interpret these high-dimensional data within a multi-omics framework. To address this limitation, we introduce DriverDBv4, an updated iteration of the DriverDB cancer driver gene database (<ext-link xlink:href="http://driverdb.bioinfomics.org/" ext-link-type="uri">http://driverdb.bioinfomics.org/</ext-link>). This updated version offers several significant enhancements: (i) an increase in the number of cohorts from 33 to 70, encompassing approximately 24 000 samples; (ii) inclusion of proteomics data, augmenting the existing types of omics data and thus expanding the analytical scope; (iii) implementation of multiple multi-omics algorithms for identification of cancer drivers; (iv) new visualization features designed to succinctly summarize high-context data and redesigned existing sections to accommodate the increased volume of datasets and (v) two new functions in Customized Analysis, specifically designed for multi-omics driver identification and subgroup expression analysis. DriverDBv4 facilitates comprehensive interpretation of multi-omics data across diverse cancer types, thereby enriching the understanding of cancer heterogeneity and aiding in the development of personalized clinical approaches. The database is designed to foster a more nuanced understanding of the multi-faceted nature of cancer.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad1060figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science and Technology Council</institution>
            <institution-id institution-id-type="DOI">10.13039/100020595</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NSTC 112-2311-B-039-001</award-id>
        <award-id>NSTC 111-2622-E-039-004</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100007300</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>CMU112-MF-25</award-id>
        <award-id>CMU111-MF-72</award-id>
        <award-id>CMU111-IP-04</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University Hospital</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004391</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>DMR-111-075</award-id>
        <award-id>DMR-112-237</award-id>
        <award-id>DMR-112-056</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100007300</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>High-throughput technology empowers the generation of comprehensive data across various omics layers and offers unparalleled insights into the molecular intricacies of cancer. Arising from perturbations in multiple omics layers, cancer necessitates a holistic approach for a broader understanding of the disease. The integration of multi-omics data provides a panoramic view of biological systems, enabling the exploration of complex relationships and identification of the different manifestations of dysregulation underlying cancer. Furthermore, the deciphering of multi-omics data promises a deeper understanding of the molecular landscape of cancer and its broader implications. Consequently, the integration of multi-omics is attracting increasing attention in cancer research and is stimulating an approach that spans multiple biological scales and fosters new insights into oncology.</p>
    <p>Several multi-omics databases or web servers, such as LinkedOmics (<xref rid="B1" ref-type="bibr">1</xref>) and UALCAN (<xref rid="B2" ref-type="bibr">2</xref>), have used statistical models like Pearson/Spearman correlation and the Kaplan–Meier method to analyze correlations between omics or between clinical features. However, such canonical methods can only attempt pairwise integration of omics since they are not designed to handle data at higher dimensions. In recent years, advancements in mathematical methods, such as matrix deconvolution, machine learning, and network approaches, have significantly enhanced multi-omics integration technology. While these novel methodologies have the potential to offer a broad and thorough understanding of cancer, which involves numerous factors that interact dynamically, application of multi-omics integration methods to decipher cancer drivers is still necessary and remains inadequate.</p>
    <p>DriverDB is a cancer driver gene database that has been in use since 2014 (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). The most recent release, DriverDBv4, has significantly enhanced capabilities and expanded datasets. In addition, DriverDBv4 has incorporated proteome data, allowing a deeper understanding of the molecular landscape. The database employs various approaches to comprehensively dissect cancer drivers by exploiting multi-omics integration methodologies. The user interface has been carefully improved to include new visualization plots that accurately show the integration of multi-omics data. Two new functions have been added to the ‘Customized Analysis’ section. Overall, DriverDBv4 allows researchers to explore the complex relationships between cancers and driver genes.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p>The updated DriverDBv4 has 25 509 cancer patient samples across six types of omics. In addition to 33 cancer types with 10 914 patients from The Cancer Genome Atlas Program (TCGA) (<xref rid="B5" ref-type="bibr">5</xref>), 37 cancer types with &gt;14 595 patients from the International Cancer Genome Consortium (ICGC) (<xref rid="B6" ref-type="bibr">6</xref>), Therapeutically Applicable Research to Generate Effective Targets (TARGET) (<xref rid="B7" ref-type="bibr">7</xref>), and The Sweden Cancerome Analysis Network-Breast (SCAN-B) (<xref rid="B9" ref-type="bibr">9</xref>) were included in the updated DriverDBv4.</p>
      <p>Omics data and corresponding clinical data from TCGA, ICGC, and TARGET were obtained through TCGAbiolinks (<xref rid="B8" ref-type="bibr">8</xref>). Data on gene expression, along with corresponding clinical features of SCAN-B, were curated from GSE81540 and their original paper (<xref rid="B9" ref-type="bibr">9</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). Molecular subgroup classifications of patients, such as lumina A and lumina B for BRCA, were obtained from TCGAbiolinks (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>) in order to help users to define patient groups in ‘Customized Analysis’.</p>
      <p>Protein abundances of all 32 cancer types released from TCGA were assessed by the reverse phase protein array which was designed to quantify both abundances of total protein and protein with post-translational modifications (<xref rid="B10" ref-type="bibr">10</xref>). TCGAbiolinks provided the protein abundance values without further processing as the expression values had been normalized.</p>
      <p>Patients’ clinical features were selected and curated by oncologists and records without clinical information, such as the submission date, were removed. Furthermore, records with duplicated information were merged according to oncologists’ suggestions; for example, her2 status was judged based on immunohistochemistry status and fluorescence <italic toggle="yes">in situ</italic> hybridization outcomes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Multi-omics integration algorithm</title>
      <p>DriverDBv4 includes eight multi-omics integration algorithms, CoMEt (<xref rid="B11" ref-type="bibr">11</xref>), DawnRank (<xref rid="B12" ref-type="bibr">12</xref>), MOFA (<xref rid="B13" ref-type="bibr">13</xref>), DIABLO (<xref rid="B14" ref-type="bibr">14</xref>), DriverSubNet (<xref rid="B15" ref-type="bibr">15</xref>), OPLSDA (<xref rid="B16" ref-type="bibr">16</xref>), SDGCCA (<xref rid="B17" ref-type="bibr">17</xref>) and SGCCA (<xref rid="B18" ref-type="bibr">18</xref>), which are used to interpret multi-omics driver features. A matrix deconvolution method, e.g. MOFA, was used to identify the multi-omics factors that capture most of the variation in each omics dataset. Canonical correlation analysis methods, such as SGCCA, SDGCCA and DIABLO, performed linear transformations of each omics dataset to achieve the highest correlation between the data from the multiple omics datasets and clinical data. Linear discriminant analysis methods, such as OPLSDA, identified a linear combination of features from multi-omics data that separated two classes. Network approaches, such as DawnRank and DriverSubNet, integrated different omics data from heterogeneous layers into a single network or sub-network. A statistical approach, CoMEt, was used to identify combinations of mutually exclusive changes across omics. The multi-omics analysis was conducted on datasets derived from four different types of omics data, each with a sample size exceeding five. Further information on each algorithm is provided in supplementary methods and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <p>DriverDBv4 offers three sections, ‘Cancer,’ ‘Gene’ and ‘Customized analysis’, to analyze several molecular features of cancer. New functions have been added to the three sections to promote the integration of individual omics datasets, enabling researchers to investigate the intricate interactions between multiple omics layers.</p>
    <sec id="SEC3-1">
      <title>Cancer</title>
      <p>A new panel, termed ‘multi-omics,’ has been added specifically to integrate multi-omics data and offers a fresh perspective on studying cancer hallmark genes (Figure <xref rid="F1" ref-type="fig">1A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2A</xref>). This panel allows researchers to not only explore the contributions of various omics to the driver genes but also simultaneously link biological functions to the specific cancer of interest (Figure <xref rid="F1" ref-type="fig">1B</xref>). Furthermore, this new information is also added to the pre-existing summary page to visualize the intricate network connections between multi-omics driver genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2B</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Multi-omics integration in DriverDBv4. (<bold>A</bold>) Genes identified by multi-omics integration algorithms are summarized. The distribution of top 30 genes among different omics layers are shown in a heatmap (upper panel) and are ranked by the number of tools which identify the gene in a dodged bar chart (bottom panel). The features were ranked according to both the number of omics and the number of tools utilized to identify these drivers. (<bold>B</bold>) A Sankey diagram is used to demonstrate the relationship between genes in multi-omics and corresponding biological functions. (<bold>C</bold>) A multi-omics plot depicts the interplay of multiple omics characteristics of a specific gene among several cancers. The black solid dot represents the gene that is identified by at least one multi-omics integration algorithm and linked together by a black line (right-bottom panel). The distribution of the number of a gene identified by algorithms is depicted in a bar chart according to the cancer axis (upper-right panel) or the omics axis (bottom-left panel), respectively.</p>
        </caption>
        <graphic xlink:href="gkad1060fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Gene</title>
      <p>Genes that exhibit driver features in various cancer types are of significant value for allocating crucial biological functions shared by cancers. The new "multi-omics" panel in the Gene section evaluates not only the importance of a gene as a multi-omics driver but also how vital the gene is for various cancer types (Figure <xref rid="F1" ref-type="fig">1C</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3A</xref>). The integration of multi-omics data analysis through the Gene section empowers researchers to explore multi-omics drivers and evaluate them across several cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3B</xref>).</p>
      <p>Protein abundance and post-translational modifications (PTMs), such as RTK phosphorylation, have previously been established as significant factors of cancer heterogeneity. These modifications have been found to correlate with patient survival (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). In the new ‘Protein’ panel, DriverDBv4 assists researchers to identify differences in protein abundance, including various PTMs, between several cancers and gain a comprehensive understanding of cancer heterogeneity at the proteomic level (Figure <xref rid="F2" ref-type="fig">2A</xref>). Researchers can also evaluate the protein at different tumor stages or mutation statuses. In addition, enrichment of highly correlated transcript and protein levels is associated with reduced patient survival and aggressive disease (<xref rid="B21" ref-type="bibr">21</xref>). To help researchers explore such <italic toggle="yes">cis-</italic>regulation, DriverDBv4 analyzes transcript–protein pairs and summarizes results to provide a pan-cancer view with detailed information (Figure <xref rid="F2" ref-type="fig">2B</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Protein analysis in DriverDBv4. (<bold>A</bold>) The protein abundance distribution among various cancer types is depicted in a box plot stratified by the tumor stage or the mutation status (left panel). The detailed distribution in a specific cancer can also be explored (right panel). (<bold>B</bold>) Correlation coefficients between protein and RNA expression of several cancer types are summarized in a bar chart (left panel). Different PTMs, such as phosphorylation on different tyrosine sites (pY1068 and pY1173) of EGFR, are depicted in different colors for visualization and the statistical analysis result is shown in a dot plot (right panel).</p>
        </caption>
        <graphic xlink:href="gkad1060fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-3">
      <title>Customized analysis</title>
      <p>Different subtypes of the same cancer class usually vary in drug response and survival risk (<xref rid="B22" ref-type="bibr">22</xref>). Therefore, identifying multi-omics hallmarks of different cancer subtypes is crucial for personalized clinical approaches (<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>). To address this issue, DriverDBv4 has developed two new functions, ‘Multi-omics Driver Analysis’ and ‘Subgroup Expression Analysis,’ which allow researchers to analyze the features differing between groups. The ‘Multi-omics Driver Analysis’ function aims to uncover underlying differences in multi-omics between groups of cancer patients. A compelling example is the exploration of her2-positive breast cancer-associated multi-omics features by contrasting her2-positive and her2-negative patients in BRCA-TCGA, which led to the identification of key her2-related genes, such as ERBB2 and MED1, known to jointly influence her2-positive tumor progression (Figure <xref rid="F1" ref-type="fig">1A</xref>, bottom) (<xref rid="B25" ref-type="bibr">25</xref>). The other function, ‘Subgroup Expression Analysis’, examines differences in gene expression in patients with distinct clinical features, such as tumor neoplasm grade. For example, the pronounced variability in PTTG1 expression between different neoplasm grades in KIRC-TCGA (Figure <xref rid="F3" ref-type="fig">3</xref>). The upregulation of PTTG1 in advanced stages, as well as its elevation compared to its level in normal tissue, supports previous findings (<xref rid="B26" ref-type="bibr">26</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>An example of subgroup expression analysis in customized analysis. This violin plot showcases the differential expression between user-defined subgroups based on tumor neoplasm histological grades. Analysis includes patients from the TCGA-KIRC cohort with recorded tumor histological grades. Grades G1 through G4 correspond to neoplasm histological grades 1 to 4, respectively. When available, the normal tissue (NT) is also evaluated. Levels of significance are denoted as follows: * (<italic toggle="yes">P</italic> &lt; 0.05), ** (<italic toggle="yes">P</italic> &lt; 0.01), *** (<italic toggle="yes">P</italic> &lt; 0.001) and **** (<italic toggle="yes">P</italic> &lt; 0.0001).</p>
        </caption>
        <graphic xlink:href="gkad1060fig3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>DriverDBv4 uses various multi-omics integration algorithms to identify drivers in the complex landscape of cancer and presents these drivers with remarkable clarity, making them easily understandable to the scientific community. Apart from exploring pairwise correlations of omics (such as the information provided by DriverDBv3, LinkedOmics, and UALCAN), DriverDBv4 clarifies intricate driver relationships between multiple omics datasets to provide new insights simultaneously. Researchers can explore multi-omics factors along two axes, ‘Cancer’ and ‘Gene’, according to their specific research requirements. ‘Customized Analysis’ can empower researchers to conduct personalized multi-omics analyses regardless of their programming skills. These advancements in DriverDBv4 are likely to significantly support researchers deciphering the complexities of cancer.</p>
    <p>Several cancer driver databases have previously been published, including IntOGen (<xref rid="B27" ref-type="bibr">27</xref>), OncoVar (<xref rid="B28" ref-type="bibr">28</xref>), and our earlier version, DriverDBv3 (refer to <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>). OncoVar identifies driver genes from the perspective of positive selection in cancer by linking mutation drivers to pathways to analyze potential underlying mechanisms. IntOGen examines various mutation properties and identifies driver genes from the perspective of positive selection in cancer. As shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>, DriverDBv4 expanded a broader range of datasets, incorporated proteomics data, two additional customized analyses, and provided an analysis of multi-omics integration. In DriverDBv3, we evaluated single-omics drivers based on a combination of data from multiple omics sources, as for the methylation driver based on data from both methylation and expression. By incorporating several multi-omics integration algorithms into DriverDBv4, we integrated these drivers defined in DriverDBv3 in a systematic manner to identify potential multi-omics drivers, such as ERBB2 and MED1, which are known to jointly influence the progression of her2-positive tumors (see Figure <xref rid="F1" ref-type="fig">1A</xref>).</p>
    <p>The ‘Cancer’ section of DriverDBv4 enables researchers to identify the complex characteristics of different types of cancer. For example, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 4A</xref> and Figure <xref rid="F1" ref-type="fig">1B</xref> show the multi-omics drivers in breast cancer. The dual impact of the major gene, PIK3R1, on cancer progression is manifested through both mutational and transcriptional layers (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>). The underexpression of PIK3R1 has been reported as a useful prognostic marker of breast cancer, highlighting its diverse role in disease progression (<xref rid="B29" ref-type="bibr">29</xref>). This emphasizes DriverDBv4’s potential for helping researchers uncover cancer's multidimensional nature.</p>
    <p>The ‘Gene’ section helps researchers explore the molecular properties of a specific driver gene and identify its significance for different cancer types. For example, downregulation of expression or loss-of-function mutations of CDH1 (E-cadherin) may disrupt the maintenance of cell adhesion, cell polarity, and epithelial–mesenchymal transition, thus contributing to invasive tumor behavior (<xref rid="B30" ref-type="bibr">30</xref>). In DriverDBv4, CDH1 is identified as a multi-omics driver in several cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 5</xref>), including hepatocellular carcinoma, bladder cancer, breast cancer, and colon cancer (<xref rid="B31" ref-type="bibr">31–34</xref>). This exemplifies the pan-cancer impact of specific genes and illustrates the crucial role of CDH1 as a driver gene in cancer progression. DriverDBv4 can help researchers explore the molecular underpinnings of driver genes across different cancer types and evaluate their pan-cancer significance.</p>
    <p>The proteomic analysis in DriverDBv4 enables researchers to explore noteworthy proteins in cancer and addresses the insufficiency of transcript levels for representing protein levels in many scenarios (<xref rid="B35" ref-type="bibr">35</xref>). Researchers can investigate protein abundance distributions, considering various PTMs, and compare them between different pathological stages and mutation states (Figure <xref rid="F2" ref-type="fig">2A</xref>). It has been suggested that mRNA and protein correlation analysis may reveal potential candidates for anticancer therapy (<xref rid="B36" ref-type="bibr">36</xref>). For example, a high correlation between RNA and protein levels in ERBB2 in BRCA (Figure <xref rid="F2" ref-type="fig">2B</xref>, right panel) has been reported with therapeutic opportunities (<xref rid="B10" ref-type="bibr">10</xref>). Moreover, different PTMs, such as phosphorylation at Tyr1068 and Tyr1173 of EGFR, exert multifaceted impacts on cancer therapy outcomes (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>). Although both modifications activate EGFR, the phosphorylation of Tyr1173 in EGFR is affected by more factors, such as mutation, than that of Tyr1068 (<xref rid="B39" ref-type="bibr">39</xref>). This implies that the RNA of EGFR is insufficient to represent the abundance of Tyr1173, resulting in a weaker correlation than Tyr1068, which is not affected by other factors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3C</xref>). These findings demonstrate the importance of investigating the correlations between mRNA and protein/PTMs.</p>
    <p>To accommodate the expanded datasets and new multi-omics integration results, we have redesigned the visualizations to provide a comprehensive summary of the data. In particular, the Gene section features the Multi-Omics Plot (Figure <xref rid="F1" ref-type="fig">1C</xref>, bottom right), which illustrates the overlap between omics across cancer types and helps researchers compare multi-omics features at a glance. The bar charts (Figure <xref rid="F1" ref-type="fig">1C</xref>, top right and bottom left) provide insights into the distribution of omics and cancer types. A Sankey diagram (Figure <xref rid="F1" ref-type="fig">1B</xref>) establishes connections between omics, genes, and biological functions, revealing the top multi-omics features and their functional implications. Our redesigned figures show single-/multi-omics drivers in the heatmap and network plot in the ‘Gene’ section summary (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figures 2B and 3B</xref>). Furthermore, a new ‘Protein’ panel introduces interactive plots that highlight protein abundances (Figure <xref rid="F2" ref-type="fig">2A</xref>) and their corresponding mRNA associations (Figure <xref rid="F2" ref-type="fig">2B</xref>). By incorporating such dynamic visualizations and promoting multi-omics integration, DriverDBv4 enhances the understanding of intricate molecular interactions and provides a vital resource for researchers.</p>
    <p>The novel custom analysis introduced in this updated version enables researchers to unravel complex multi-omics features across patient groups and uncover differences in expression patterns associated with specific clinical features of personal interest. ‘Multi-omics Identification’ allows the exploration of multi-omics feature segregation between groups, enabling the identification of potential driver genes in multi-omics layers, such as the joint influence of ERBB2 and MED1 on her2-positive BRCA progression (<xref rid="B25" ref-type="bibr">25</xref>). In addition, ‘Subgroup Expression Analysis’ delves into comprehensive expression patterns, such as PTTG1 up-regulation in advanced KIRC (<xref rid="B26" ref-type="bibr">26</xref>). These demonstrates that the customized analysis enables researchers to independently validate genes or multi-omics features of interest, thereby improving their investigations with robust insights derived from DriverDBv4.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad1060_Supplemental_File</label>
      <media xlink:href="gkad1060_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We thank to National Center for High-performance Computing (NCHC) for providing computational and storage resources.</p>
    <p><italic toggle="yes">Author contributions</italic>: C.H.L. conducts all analyses and designs the database. Y.L.L. and C.H.L. wrote the manuscript. Y.L.L. and Y.D.W. access clinical features for customized analysis. P.C.S. layouts and designs figures. H.C.L. and M.H.T. design the interactive web interface. W.J.L., F.H.C., C.Y.L. and S.C.W. curated the data. W.C.C. revises the final version of the manuscript.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>The DriverDB database will be continuously maintained and updated. The database is now publicly accessible at <ext-link xlink:href="http://driverdb.bioinfomics.org/" ext-link-type="uri">http://driverdb.bioinfomics.org/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad1060#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Science and Technology Council, Taiwan, R.O.C. [NSTC 112-2311-B-039-001 and NSTC 111-2622-E-039-004]; China Medical University, Taiwan, R.O.C. [CMU112-MF-25, CMU111-MF-72, CMU111-IP-04]; China Medical University Hospital, Taiwan, R.O.C. [DMR-111-075, DMR-112-237, DMR-112-056]; ‘Cancer Biology and Precision Therapeutics Center, China Medical University’ from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (in part). Funding for open access charge: National Science and Technology Council, Taiwan, R.O.C.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vasaikar</surname><given-names>S.V.</given-names></string-name>, <string-name><surname>Straub</surname><given-names>P.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name></person-group><article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>46</volume>:<fpage>D956</fpage>–<lpage>D963</lpage>.</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chandrashekar</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Karthikeyan</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Korla</surname><given-names>P.K.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>H.</given-names></string-name>, <string-name><surname>Shovon</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Athar</surname><given-names>M.</given-names></string-name>, <string-name><surname>Netto</surname><given-names>G.J.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Z.S.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Manne</surname><given-names>U.</given-names></string-name><etal>et al</etal>.</person-group><article-title>UALCAN: an update to the integrated cancer data analysis platform</article-title>. <source>Neoplasia</source>. <year>2022</year>; <volume>25</volume>:<fpage>18</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">35078134</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>I.F.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Fen</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>T.Y.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.W.</given-names></string-name></person-group><article-title>DriverDB: an exome sequencing database for cancer driver gene identification</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D1048</fpage>–<lpage>D1054</lpage>.<pub-id pub-id-type="pmid">24214964</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>S.-H.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>P.-C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.-Y.</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>A.-N.</given-names></string-name>, <string-name><surname>Cho</surname><given-names>Y.-C.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>Y.-L.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>F.-H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.-Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.-C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DriverDBv3: a multi-omics database for cancer driver gene research</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D863</fpage>–<lpage>D870</lpage>.<pub-id pub-id-type="pmid">31701128</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Collisson</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Mills</surname><given-names>G.B.</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Ozenberger</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Ellrott</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shmulevich</surname><given-names>I.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>J.M.</given-names></string-name></person-group><article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat. Genet.</source><year>2013</year>; <volume>45</volume>:<fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hudson</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>W.</given-names></string-name>, <string-name><surname>Artez</surname><given-names>A.</given-names></string-name>, <string-name><surname>Barker</surname><given-names>A.D.</given-names></string-name>, <string-name><surname>Bell</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bernabé</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Bhan</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Calvo</surname><given-names>F.</given-names></string-name>, <string-name><surname>Eerola</surname><given-names>I.</given-names></string-name>, <string-name><surname>Gerhard</surname><given-names>D.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>International network of cancer genome projects</article-title>. <source>Nature</source>. <year>2010</year>; <volume>464</volume>:<fpage>993</fpage>–<lpage>998</lpage>.<pub-id pub-id-type="pmid">20393554</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Alexandrov</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Edmonson</surname><given-names>M.N.</given-names></string-name>, <string-name><surname>Gawad</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Rusch</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Easton</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours</article-title>. <source>Nature</source>. <year>2018</year>; <volume>555</volume>:<fpage>371</fpage>–<lpage>376</lpage>.<pub-id pub-id-type="pmid">29489755</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colaprico</surname><given-names>A.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Olsen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Garofano</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cava</surname><given-names>C.</given-names></string-name>, <string-name><surname>Garolini</surname><given-names>D.</given-names></string-name>, <string-name><surname>Sabedot</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Malta</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Pagnotta</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Castiglioni</surname><given-names>I.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>e71</fpage>.<pub-id pub-id-type="pmid">26704973</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saal</surname><given-names>L.H.</given-names></string-name>, <string-name><surname>Vallon-Christersson</surname><given-names>J.</given-names></string-name>, <string-name><surname>Häkkinen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hegardt</surname><given-names>C.</given-names></string-name>, <string-name><surname>Grabau</surname><given-names>D.</given-names></string-name>, <string-name><surname>Winter</surname><given-names>C.</given-names></string-name>, <string-name><surname>Brueffer</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Reuterswärd</surname><given-names>C.</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine</article-title>. <source>Genome Med.</source><year>2015</year>; <volume>7</volume>:<fpage>20</fpage>.<pub-id pub-id-type="pmid">25722745</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akbani</surname><given-names>R.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>P.K.S.</given-names></string-name>, <string-name><surname>Werner</surname><given-names>H.M.J.</given-names></string-name>, <string-name><surname>Shahmoradgoli</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ju</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.-Y.</given-names></string-name>, <string-name><surname>Yoshihara</surname><given-names>K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A pan-cancer proteomic perspective on The Cancer Genome Atlas</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>3887</fpage>.<pub-id pub-id-type="pmid">24871328</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leiserson</surname><given-names>M.D.M.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>H.-T.</given-names></string-name>, <string-name><surname>Vandin</surname><given-names>F.</given-names></string-name>, <string-name><surname>Raphael</surname><given-names>B.J.</given-names></string-name></person-group><article-title>CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer</article-title>. <source>Genome Biol.</source><year>2015</year>; <volume>16</volume>:<fpage>160</fpage>.<pub-id pub-id-type="pmid">26253137</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hou</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name></person-group><article-title>DawnRank: discovering personalized driver genes in cancer</article-title>. <source>Genome Medicine</source>. <year>2014</year>; <volume>6</volume>:<fpage>56</fpage>.<pub-id pub-id-type="pmid">25177370</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Argelaguet</surname><given-names>R.</given-names></string-name>, <string-name><surname>Arnol</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bredikhin</surname><given-names>D.</given-names></string-name>, <string-name><surname>Deloro</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Velten</surname><given-names>B.</given-names></string-name>, <string-name><surname>Marioni</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Stegle</surname><given-names>O.</given-names></string-name></person-group><article-title>MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data</article-title>. <source>Genome Biol.</source><year>2020</year>; <volume>21</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">32393329</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>A.</given-names></string-name>, <string-name><surname>Shannon</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Gautier</surname><given-names>B.</given-names></string-name>, <string-name><surname>Rohart</surname><given-names>F.</given-names></string-name>, <string-name><surname>Vacher</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tebbutt</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Lê Cao</surname><given-names>K.-A.</given-names></string-name></person-group><article-title>DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays</article-title>. <source>Bioinformatics</source>. <year>2019</year>; <volume>35</volume>:<fpage>3055</fpage>–<lpage>3062</lpage>.<pub-id pub-id-type="pmid">30657866</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bin</surname><given-names>Y.</given-names></string-name></person-group><article-title>DriverSubNet: a novel algorithm for identifying cancer driver genes by subnetwork enrichment analysis</article-title>. <source>Front. Genet.</source><year>2021</year>; <volume>11</volume>:<fpage>607798</fpage>.<pub-id pub-id-type="pmid">33679866</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thévenot</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Roux</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ezan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Junot</surname><given-names>C.</given-names></string-name></person-group><article-title>Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses</article-title>. <source>J. Proteome Res.</source><year>2015</year>; <volume>14</volume>:<fpage>3322</fpage>–<lpage>3335</lpage>.<pub-id pub-id-type="pmid">26088811</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moon</surname><given-names>S.</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>H.</given-names></string-name></person-group><article-title>SDGCCA: supervised deep generalized canonical correlation analysis for multi-omics integration</article-title>. <source>J. Comput. Biol.</source><year>2022</year>; <volume>29</volume>:<fpage>892</fpage>–<lpage>907</lpage>.<pub-id pub-id-type="pmid">35951002</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tenenhaus</surname><given-names>A.</given-names></string-name>, <string-name><surname>Philippe</surname><given-names>C.</given-names></string-name>, <string-name><surname>Guillemot</surname><given-names>V.</given-names></string-name>, <string-name><surname>Le Cao</surname><given-names>K.-A.</given-names></string-name>, <string-name><surname>Grill</surname><given-names>J.</given-names></string-name>, <string-name><surname>Frouin</surname><given-names>V.</given-names></string-name></person-group><article-title>Variable selection for generalized canonical correlation analysis</article-title>. <source>Biostatistics</source>. <year>2014</year>; <volume>15</volume>:<fpage>569</fpage>–<lpage>583</lpage>.<pub-id pub-id-type="pmid">24550197</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Djuric</surname><given-names>U.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>K.H.B.</given-names></string-name>, <string-name><surname>Kao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Batruch</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jevtic</surname><given-names>S.</given-names></string-name>, <string-name><surname>Papaioannou</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Diamandis</surname><given-names>P.</given-names></string-name></person-group><article-title>Defining protein pattern differences among molecular subtypes of diffuse gliomas using mass spectrometry</article-title>. <source>Mol. Cell. Proteomics</source>. <year>2019</year>; <volume>18</volume>:<fpage>2029</fpage>–<lpage>2043</lpage>.<pub-id pub-id-type="pmid">31353322</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Butti</surname><given-names>R.</given-names></string-name>, <string-name><surname>Das</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gunasekaran</surname><given-names>V.P.</given-names></string-name>, <string-name><surname>Yadav</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kundu</surname><given-names>G.C.</given-names></string-name></person-group><article-title>Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges</article-title>. <source>Mol. Cancer</source>. <year>2018</year>; <volume>17</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">29455658</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Dorsey</surname><given-names>T.H.</given-names></string-name>, <string-name><surname>Prieto</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.W.</given-names></string-name>, <string-name><surname>Ruppin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Veenstra</surname><given-names>T.D.</given-names></string-name>, <string-name><surname>Ambs</surname><given-names>S.</given-names></string-name></person-group><article-title>Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival</article-title>. <source>Genome Medicine</source>. <year>2018</year>; <volume>10</volume>:<fpage>94</fpage>.<pub-id pub-id-type="pmid">30501643</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>ten Hoorn</surname><given-names>S.</given-names></string-name>, <string-name><surname>de Back</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Sommeijer</surname><given-names>D.W.</given-names></string-name>, <string-name><surname>Vermeulen</surname><given-names>L.</given-names></string-name></person-group><article-title>Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta analysis</article-title>. <source>J. Natl. Cancer Inst.</source><year>2021</year>; <volume>114</volume>:<fpage>503</fpage>–<lpage>516</lpage>.</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>F.</given-names></string-name>, <string-name><surname>Guan</surname><given-names>M.</given-names></string-name></person-group><article-title>Delving into the heterogeneity of different breast cancer subtypes and the prognostic models utilizing scRNA-Seq and bulk RNA-Seq</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>:<fpage>9936</fpage>.<pub-id pub-id-type="pmid">36077333</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>He</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Liao</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ren</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma</article-title>. <source>Clin. Cancer Res.</source><year>2022</year>; <volume>28</volume>:<fpage>1896</fpage>–<lpage>1910</lpage>.<pub-id pub-id-type="pmid">34526363</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Leonard</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Mahmoud</surname><given-names>C.</given-names></string-name>, <string-name><surname>Khan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lower</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><article-title>HER2-driven breast tumorigenesis relies upon interactions of the estrogen receptor with coactivator MED1</article-title>. <source>Cancer Res.</source><year>2018</year>; <volume>78</volume>:<fpage>422</fpage>–<lpage>435</lpage>.<pub-id pub-id-type="pmid">29187405</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gui</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>P.</given-names></string-name></person-group><article-title>Overexpressing PTTG family genes predict poor prognosis in kidney renal clear cell carcinoma</article-title>. <source>World J. Surg. Oncol.</source><year>2021</year>; <volume>19</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">33845847</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Kuang</surname><given-names>X.Y.</given-names></string-name>, <string-name><surname>Zuo</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>F.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Z.G.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>S.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>1357</fpage>.<pub-id pub-id-type="pmid">29636477</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kołodziej</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nicoś</surname><given-names>M.</given-names></string-name>, <string-name><surname>Krawczyk</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Bogucki</surname><given-names>J.</given-names></string-name>, <string-name><surname>Karczmarczyk</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zalewski</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kubrak</surname><given-names>T.</given-names></string-name>, <string-name><surname>Kołodziej</surname><given-names>E.</given-names></string-name>, <string-name><surname>Makuch-Kocka</surname><given-names>A.</given-names></string-name>, <string-name><surname>Madej-Czerwonka</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The correlation of mutations and expressions of genes within the PI3K/Akt/mTOR pathway in breast cancer - a preliminary study</article-title>. <source>Int. J. Mol. Sci.</source><year>2021</year>; <volume>22</volume>:<fpage>2061</fpage>.<pub-id pub-id-type="pmid">33669698</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cizkova</surname><given-names>M.</given-names></string-name>, <string-name><surname>Vacher</surname><given-names>S.</given-names></string-name>, <string-name><surname>Meseure</surname><given-names>D.</given-names></string-name>, <string-name><surname>Trassard</surname><given-names>M.</given-names></string-name>, <string-name><surname>Susini</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mlcuchova</surname><given-names>D.</given-names></string-name>, <string-name><surname>Callens</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rouleau</surname><given-names>E.</given-names></string-name>, <string-name><surname>Spyratos</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lidereau</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PIK3R1 underexpression is an independent prognostic marker in breast cancer</article-title>. <source>BMC Cancer</source>. <year>2013</year>; <volume>13</volume>:<fpage>545</fpage>.<pub-id pub-id-type="pmid">24229379</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shenoy</surname><given-names>S.</given-names></string-name></person-group><article-title>CDH1 (E-Cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management</article-title>. <source>Cancer Manag. Res.</source><year>2019</year>; <volume>11</volume>:<fpage>10477</fpage>–<lpage>10486</lpage>.<pub-id pub-id-type="pmid">31853199</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname><given-names>T.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>L.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>B.</given-names></string-name>, <string-name><surname>He</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Han</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y.</given-names></string-name></person-group><article-title>CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration</article-title>. <source>BMC Urol.</source><year>2022</year>; <volume>22</volume>:<fpage>156</fpage>.<pub-id pub-id-type="pmid">36131343</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pomo</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Gullapalli</surname><given-names>R.R.</given-names></string-name></person-group><article-title>Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics</article-title>. <source>Cancer Cell Int.</source><year>2016</year>; <volume>16</volume>:<fpage>44</fpage>.<pub-id pub-id-type="pmid">27303212</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>F.M.</given-names></string-name>, <string-name><surname>McKee</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Rajpar</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Evans</surname><given-names>D.G.</given-names></string-name>, <string-name><surname>Jankowski</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>McKeown</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sanders</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Maher</surname><given-names>E.R.</given-names></string-name></person-group><article-title>Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer</article-title>. <source>Hum. Mol. Genet.</source><year>1999</year>; <volume>8</volume>:<fpage>607</fpage>–<lpage>610</lpage>.<pub-id pub-id-type="pmid">10072428</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname><given-names>D.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pei</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>T.</given-names></string-name></person-group><article-title>The potential role of CDH1 as an oncogene combined with related miRNAs and their diagnostic value in breast cancer</article-title>. <source>Front. Endocrinol. (Lausanne)</source>. <year>2022</year>; <volume>13</volume>:<fpage>916469</fpage>.<pub-id pub-id-type="pmid">35784532</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Beyer</surname><given-names>A.</given-names></string-name>, <string-name><surname>Aebersold</surname><given-names>R.</given-names></string-name></person-group><article-title>On the dependency of cellular protein levels on mRNA abundance</article-title>. <source>Cell</source>. <year>2016</year>; <volume>165</volume>:<fpage>535</fpage>–<lpage>550</lpage>.<pub-id pub-id-type="pmid">27104977</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andrieux</surname><given-names>G.</given-names></string-name>, <string-name><surname>Chakraborty</surname><given-names>S.</given-names></string-name>, <string-name><surname>Das</surname><given-names>T.</given-names></string-name>, <string-name><surname>Boerries</surname><given-names>M.</given-names></string-name></person-group><article-title>Alteration of proteotranscriptomic landscape reveals the transcriptional regulatory circuits controlling key-signaling pathways and metabolic reprogramming during tumor evolution</article-title>. <source>Front. Cell Dev. Biol.</source><year>2020</year>; <volume>8</volume>:<fpage>586479</fpage>.<pub-id pub-id-type="pmid">33384992</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Duan</surname><given-names>J.</given-names></string-name>, <string-name><surname>An</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>the Key Laboratory of</surname><given-names>C.</given-names></string-name>, <string-name><surname>Translational</surname><given-names>R.</given-names></string-name></person-group><article-title>Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR</article-title>. <source>J. Exp. Clin. Cancer Res.</source><year>2012</year>; <volume>31</volume>:<fpage>65</fpage>.<pub-id pub-id-type="pmid">22901364</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sette</surname><given-names>G.</given-names></string-name>, <string-name><surname>Salvati</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mottolese</surname><given-names>M.</given-names></string-name>, <string-name><surname>Visca</surname><given-names>P.</given-names></string-name>, <string-name><surname>Gallo</surname><given-names>E.</given-names></string-name>, <string-name><surname>Fecchi</surname><given-names>K.</given-names></string-name>, <string-name><surname>Pilozzi</surname><given-names>E.</given-names></string-name>, <string-name><surname>Duranti</surname><given-names>E.</given-names></string-name>, <string-name><surname>Policicchio</surname><given-names>E.</given-names></string-name>, <string-name><surname>Tartaglia</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer</article-title>. <source>Cell Death. Dis.</source><year>2015</year>; <volume>6</volume>:<fpage>e1850</fpage>.<pub-id pub-id-type="pmid">26247735</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zimmer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kahl</surname><given-names>P.</given-names></string-name>, <string-name><surname>Buhl</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Steiner</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wardelmann</surname><given-names>E.</given-names></string-name>, <string-name><surname>Merkelbach-Bruse</surname><given-names>S.</given-names></string-name>, <string-name><surname>Buettner</surname><given-names>R.</given-names></string-name>, <string-name><surname>Heukamp</surname><given-names>L.C.</given-names></string-name></person-group><article-title>Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling</article-title>. <source>J. Cancer Res. Clin. Oncol.</source><year>2009</year>; <volume>135</volume>:<fpage>723</fpage>–<lpage>730</lpage>.<pub-id pub-id-type="pmid">19002495</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767848</article-id>
    <article-id pub-id-type="pmid">37956338</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad1060</article-id>
    <article-id pub-id-type="publisher-id">gkad1060</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DriverDBv4: a multi-omics integration database for cancer driver gene research</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Chia-Hsin</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lai</surname>
          <given-names>Yo-Liang</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shen</surname>
          <given-names>Pei-Chun</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Hsiu-Cheng</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tsai</surname>
          <given-names>Meng-Hsin</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yu-De</given-names>
        </name>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Department of Urology, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lin</surname>
          <given-names>Wen-Jen</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>School of Medicine, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Fang-Hsin</given-names>
        </name>
        <aff><institution>Institute of Nuclear Engineering and Science, National Tsing Hua University</institution>, <addr-line>Hsinchu 300044</addr-line>, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Chia-Yang</given-names>
        </name>
        <aff><institution>Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University</institution>, Kaohsiung 80708, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Shu-Chi</given-names>
        </name>
        <aff><institution>Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University</institution>, Kaohsiung 80708, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hung</surname>
          <given-names>Mien-Chie</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Institute of Biochemistry and Molecular Biology, China Medical University</institution>, <addr-line>Taichung 404328</addr-line>, <country country="TW">Taiwan</country></aff>
        <aff><institution>Molecular Medicine Center, China Medical University Hospital, China Medical University</institution>, <addr-line>Taichung 404328</addr-line>, <country country="TW">Taiwan</country></aff>
        <aff><institution>Department of Biotechnology, Asia University</institution>, <addr-line>Taichung 413305</addr-line>, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1229-4857</contrib-id>
        <name>
          <surname>Cheng</surname>
          <given-names>Wei-Chung</given-names>
        </name>
        <!--cwc0702@gmail.com-->
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>The Ph.D. program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +886 4 2205 2121 (Ext 7820); Fax: +886 4 2233 3496; Email: <email>cwc0702@gmail.com</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-11-13">
      <day>13</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1246</fpage>
    <lpage>D1252</lpage>
    <history>
      <date date-type="accepted">
        <day>25</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad1060.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Advancements in high-throughput technology offer researchers an extensive range of multi-omics data that provide deep insights into the complex landscape of cancer biology. However, traditional statistical models and databases are inadequate to interpret these high-dimensional data within a multi-omics framework. To address this limitation, we introduce DriverDBv4, an updated iteration of the DriverDB cancer driver gene database (<ext-link xlink:href="http://driverdb.bioinfomics.org/" ext-link-type="uri">http://driverdb.bioinfomics.org/</ext-link>). This updated version offers several significant enhancements: (i) an increase in the number of cohorts from 33 to 70, encompassing approximately 24 000 samples; (ii) inclusion of proteomics data, augmenting the existing types of omics data and thus expanding the analytical scope; (iii) implementation of multiple multi-omics algorithms for identification of cancer drivers; (iv) new visualization features designed to succinctly summarize high-context data and redesigned existing sections to accommodate the increased volume of datasets and (v) two new functions in Customized Analysis, specifically designed for multi-omics driver identification and subgroup expression analysis. DriverDBv4 facilitates comprehensive interpretation of multi-omics data across diverse cancer types, thereby enriching the understanding of cancer heterogeneity and aiding in the development of personalized clinical approaches. The database is designed to foster a more nuanced understanding of the multi-faceted nature of cancer.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad1060figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science and Technology Council</institution>
            <institution-id institution-id-type="DOI">10.13039/100020595</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NSTC 112-2311-B-039-001</award-id>
        <award-id>NSTC 111-2622-E-039-004</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100007300</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>CMU112-MF-25</award-id>
        <award-id>CMU111-MF-72</award-id>
        <award-id>CMU111-IP-04</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University Hospital</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004391</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>DMR-111-075</award-id>
        <award-id>DMR-112-237</award-id>
        <award-id>DMR-112-056</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100007300</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>High-throughput technology empowers the generation of comprehensive data across various omics layers and offers unparalleled insights into the molecular intricacies of cancer. Arising from perturbations in multiple omics layers, cancer necessitates a holistic approach for a broader understanding of the disease. The integration of multi-omics data provides a panoramic view of biological systems, enabling the exploration of complex relationships and identification of the different manifestations of dysregulation underlying cancer. Furthermore, the deciphering of multi-omics data promises a deeper understanding of the molecular landscape of cancer and its broader implications. Consequently, the integration of multi-omics is attracting increasing attention in cancer research and is stimulating an approach that spans multiple biological scales and fosters new insights into oncology.</p>
    <p>Several multi-omics databases or web servers, such as LinkedOmics (<xref rid="B1" ref-type="bibr">1</xref>) and UALCAN (<xref rid="B2" ref-type="bibr">2</xref>), have used statistical models like Pearson/Spearman correlation and the Kaplan–Meier method to analyze correlations between omics or between clinical features. However, such canonical methods can only attempt pairwise integration of omics since they are not designed to handle data at higher dimensions. In recent years, advancements in mathematical methods, such as matrix deconvolution, machine learning, and network approaches, have significantly enhanced multi-omics integration technology. While these novel methodologies have the potential to offer a broad and thorough understanding of cancer, which involves numerous factors that interact dynamically, application of multi-omics integration methods to decipher cancer drivers is still necessary and remains inadequate.</p>
    <p>DriverDB is a cancer driver gene database that has been in use since 2014 (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). The most recent release, DriverDBv4, has significantly enhanced capabilities and expanded datasets. In addition, DriverDBv4 has incorporated proteome data, allowing a deeper understanding of the molecular landscape. The database employs various approaches to comprehensively dissect cancer drivers by exploiting multi-omics integration methodologies. The user interface has been carefully improved to include new visualization plots that accurately show the integration of multi-omics data. Two new functions have been added to the ‘Customized Analysis’ section. Overall, DriverDBv4 allows researchers to explore the complex relationships between cancers and driver genes.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p>The updated DriverDBv4 has 25 509 cancer patient samples across six types of omics. In addition to 33 cancer types with 10 914 patients from The Cancer Genome Atlas Program (TCGA) (<xref rid="B5" ref-type="bibr">5</xref>), 37 cancer types with &gt;14 595 patients from the International Cancer Genome Consortium (ICGC) (<xref rid="B6" ref-type="bibr">6</xref>), Therapeutically Applicable Research to Generate Effective Targets (TARGET) (<xref rid="B7" ref-type="bibr">7</xref>), and The Sweden Cancerome Analysis Network-Breast (SCAN-B) (<xref rid="B9" ref-type="bibr">9</xref>) were included in the updated DriverDBv4.</p>
      <p>Omics data and corresponding clinical data from TCGA, ICGC, and TARGET were obtained through TCGAbiolinks (<xref rid="B8" ref-type="bibr">8</xref>). Data on gene expression, along with corresponding clinical features of SCAN-B, were curated from GSE81540 and their original paper (<xref rid="B9" ref-type="bibr">9</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). Molecular subgroup classifications of patients, such as lumina A and lumina B for BRCA, were obtained from TCGAbiolinks (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>) in order to help users to define patient groups in ‘Customized Analysis’.</p>
      <p>Protein abundances of all 32 cancer types released from TCGA were assessed by the reverse phase protein array which was designed to quantify both abundances of total protein and protein with post-translational modifications (<xref rid="B10" ref-type="bibr">10</xref>). TCGAbiolinks provided the protein abundance values without further processing as the expression values had been normalized.</p>
      <p>Patients’ clinical features were selected and curated by oncologists and records without clinical information, such as the submission date, were removed. Furthermore, records with duplicated information were merged according to oncologists’ suggestions; for example, her2 status was judged based on immunohistochemistry status and fluorescence <italic toggle="yes">in situ</italic> hybridization outcomes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Multi-omics integration algorithm</title>
      <p>DriverDBv4 includes eight multi-omics integration algorithms, CoMEt (<xref rid="B11" ref-type="bibr">11</xref>), DawnRank (<xref rid="B12" ref-type="bibr">12</xref>), MOFA (<xref rid="B13" ref-type="bibr">13</xref>), DIABLO (<xref rid="B14" ref-type="bibr">14</xref>), DriverSubNet (<xref rid="B15" ref-type="bibr">15</xref>), OPLSDA (<xref rid="B16" ref-type="bibr">16</xref>), SDGCCA (<xref rid="B17" ref-type="bibr">17</xref>) and SGCCA (<xref rid="B18" ref-type="bibr">18</xref>), which are used to interpret multi-omics driver features. A matrix deconvolution method, e.g. MOFA, was used to identify the multi-omics factors that capture most of the variation in each omics dataset. Canonical correlation analysis methods, such as SGCCA, SDGCCA and DIABLO, performed linear transformations of each omics dataset to achieve the highest correlation between the data from the multiple omics datasets and clinical data. Linear discriminant analysis methods, such as OPLSDA, identified a linear combination of features from multi-omics data that separated two classes. Network approaches, such as DawnRank and DriverSubNet, integrated different omics data from heterogeneous layers into a single network or sub-network. A statistical approach, CoMEt, was used to identify combinations of mutually exclusive changes across omics. The multi-omics analysis was conducted on datasets derived from four different types of omics data, each with a sample size exceeding five. Further information on each algorithm is provided in supplementary methods and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <p>DriverDBv4 offers three sections, ‘Cancer,’ ‘Gene’ and ‘Customized analysis’, to analyze several molecular features of cancer. New functions have been added to the three sections to promote the integration of individual omics datasets, enabling researchers to investigate the intricate interactions between multiple omics layers.</p>
    <sec id="SEC3-1">
      <title>Cancer</title>
      <p>A new panel, termed ‘multi-omics,’ has been added specifically to integrate multi-omics data and offers a fresh perspective on studying cancer hallmark genes (Figure <xref rid="F1" ref-type="fig">1A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2A</xref>). This panel allows researchers to not only explore the contributions of various omics to the driver genes but also simultaneously link biological functions to the specific cancer of interest (Figure <xref rid="F1" ref-type="fig">1B</xref>). Furthermore, this new information is also added to the pre-existing summary page to visualize the intricate network connections between multi-omics driver genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2B</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Multi-omics integration in DriverDBv4. (<bold>A</bold>) Genes identified by multi-omics integration algorithms are summarized. The distribution of top 30 genes among different omics layers are shown in a heatmap (upper panel) and are ranked by the number of tools which identify the gene in a dodged bar chart (bottom panel). The features were ranked according to both the number of omics and the number of tools utilized to identify these drivers. (<bold>B</bold>) A Sankey diagram is used to demonstrate the relationship between genes in multi-omics and corresponding biological functions. (<bold>C</bold>) A multi-omics plot depicts the interplay of multiple omics characteristics of a specific gene among several cancers. The black solid dot represents the gene that is identified by at least one multi-omics integration algorithm and linked together by a black line (right-bottom panel). The distribution of the number of a gene identified by algorithms is depicted in a bar chart according to the cancer axis (upper-right panel) or the omics axis (bottom-left panel), respectively.</p>
        </caption>
        <graphic xlink:href="gkad1060fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Gene</title>
      <p>Genes that exhibit driver features in various cancer types are of significant value for allocating crucial biological functions shared by cancers. The new "multi-omics" panel in the Gene section evaluates not only the importance of a gene as a multi-omics driver but also how vital the gene is for various cancer types (Figure <xref rid="F1" ref-type="fig">1C</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3A</xref>). The integration of multi-omics data analysis through the Gene section empowers researchers to explore multi-omics drivers and evaluate them across several cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3B</xref>).</p>
      <p>Protein abundance and post-translational modifications (PTMs), such as RTK phosphorylation, have previously been established as significant factors of cancer heterogeneity. These modifications have been found to correlate with patient survival (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). In the new ‘Protein’ panel, DriverDBv4 assists researchers to identify differences in protein abundance, including various PTMs, between several cancers and gain a comprehensive understanding of cancer heterogeneity at the proteomic level (Figure <xref rid="F2" ref-type="fig">2A</xref>). Researchers can also evaluate the protein at different tumor stages or mutation statuses. In addition, enrichment of highly correlated transcript and protein levels is associated with reduced patient survival and aggressive disease (<xref rid="B21" ref-type="bibr">21</xref>). To help researchers explore such <italic toggle="yes">cis-</italic>regulation, DriverDBv4 analyzes transcript–protein pairs and summarizes results to provide a pan-cancer view with detailed information (Figure <xref rid="F2" ref-type="fig">2B</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Protein analysis in DriverDBv4. (<bold>A</bold>) The protein abundance distribution among various cancer types is depicted in a box plot stratified by the tumor stage or the mutation status (left panel). The detailed distribution in a specific cancer can also be explored (right panel). (<bold>B</bold>) Correlation coefficients between protein and RNA expression of several cancer types are summarized in a bar chart (left panel). Different PTMs, such as phosphorylation on different tyrosine sites (pY1068 and pY1173) of EGFR, are depicted in different colors for visualization and the statistical analysis result is shown in a dot plot (right panel).</p>
        </caption>
        <graphic xlink:href="gkad1060fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-3">
      <title>Customized analysis</title>
      <p>Different subtypes of the same cancer class usually vary in drug response and survival risk (<xref rid="B22" ref-type="bibr">22</xref>). Therefore, identifying multi-omics hallmarks of different cancer subtypes is crucial for personalized clinical approaches (<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>). To address this issue, DriverDBv4 has developed two new functions, ‘Multi-omics Driver Analysis’ and ‘Subgroup Expression Analysis,’ which allow researchers to analyze the features differing between groups. The ‘Multi-omics Driver Analysis’ function aims to uncover underlying differences in multi-omics between groups of cancer patients. A compelling example is the exploration of her2-positive breast cancer-associated multi-omics features by contrasting her2-positive and her2-negative patients in BRCA-TCGA, which led to the identification of key her2-related genes, such as ERBB2 and MED1, known to jointly influence her2-positive tumor progression (Figure <xref rid="F1" ref-type="fig">1A</xref>, bottom) (<xref rid="B25" ref-type="bibr">25</xref>). The other function, ‘Subgroup Expression Analysis’, examines differences in gene expression in patients with distinct clinical features, such as tumor neoplasm grade. For example, the pronounced variability in PTTG1 expression between different neoplasm grades in KIRC-TCGA (Figure <xref rid="F3" ref-type="fig">3</xref>). The upregulation of PTTG1 in advanced stages, as well as its elevation compared to its level in normal tissue, supports previous findings (<xref rid="B26" ref-type="bibr">26</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>An example of subgroup expression analysis in customized analysis. This violin plot showcases the differential expression between user-defined subgroups based on tumor neoplasm histological grades. Analysis includes patients from the TCGA-KIRC cohort with recorded tumor histological grades. Grades G1 through G4 correspond to neoplasm histological grades 1 to 4, respectively. When available, the normal tissue (NT) is also evaluated. Levels of significance are denoted as follows: * (<italic toggle="yes">P</italic> &lt; 0.05), ** (<italic toggle="yes">P</italic> &lt; 0.01), *** (<italic toggle="yes">P</italic> &lt; 0.001) and **** (<italic toggle="yes">P</italic> &lt; 0.0001).</p>
        </caption>
        <graphic xlink:href="gkad1060fig3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>DriverDBv4 uses various multi-omics integration algorithms to identify drivers in the complex landscape of cancer and presents these drivers with remarkable clarity, making them easily understandable to the scientific community. Apart from exploring pairwise correlations of omics (such as the information provided by DriverDBv3, LinkedOmics, and UALCAN), DriverDBv4 clarifies intricate driver relationships between multiple omics datasets to provide new insights simultaneously. Researchers can explore multi-omics factors along two axes, ‘Cancer’ and ‘Gene’, according to their specific research requirements. ‘Customized Analysis’ can empower researchers to conduct personalized multi-omics analyses regardless of their programming skills. These advancements in DriverDBv4 are likely to significantly support researchers deciphering the complexities of cancer.</p>
    <p>Several cancer driver databases have previously been published, including IntOGen (<xref rid="B27" ref-type="bibr">27</xref>), OncoVar (<xref rid="B28" ref-type="bibr">28</xref>), and our earlier version, DriverDBv3 (refer to <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>). OncoVar identifies driver genes from the perspective of positive selection in cancer by linking mutation drivers to pathways to analyze potential underlying mechanisms. IntOGen examines various mutation properties and identifies driver genes from the perspective of positive selection in cancer. As shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>, DriverDBv4 expanded a broader range of datasets, incorporated proteomics data, two additional customized analyses, and provided an analysis of multi-omics integration. In DriverDBv3, we evaluated single-omics drivers based on a combination of data from multiple omics sources, as for the methylation driver based on data from both methylation and expression. By incorporating several multi-omics integration algorithms into DriverDBv4, we integrated these drivers defined in DriverDBv3 in a systematic manner to identify potential multi-omics drivers, such as ERBB2 and MED1, which are known to jointly influence the progression of her2-positive tumors (see Figure <xref rid="F1" ref-type="fig">1A</xref>).</p>
    <p>The ‘Cancer’ section of DriverDBv4 enables researchers to identify the complex characteristics of different types of cancer. For example, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 4A</xref> and Figure <xref rid="F1" ref-type="fig">1B</xref> show the multi-omics drivers in breast cancer. The dual impact of the major gene, PIK3R1, on cancer progression is manifested through both mutational and transcriptional layers (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>). The underexpression of PIK3R1 has been reported as a useful prognostic marker of breast cancer, highlighting its diverse role in disease progression (<xref rid="B29" ref-type="bibr">29</xref>). This emphasizes DriverDBv4’s potential for helping researchers uncover cancer's multidimensional nature.</p>
    <p>The ‘Gene’ section helps researchers explore the molecular properties of a specific driver gene and identify its significance for different cancer types. For example, downregulation of expression or loss-of-function mutations of CDH1 (E-cadherin) may disrupt the maintenance of cell adhesion, cell polarity, and epithelial–mesenchymal transition, thus contributing to invasive tumor behavior (<xref rid="B30" ref-type="bibr">30</xref>). In DriverDBv4, CDH1 is identified as a multi-omics driver in several cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 5</xref>), including hepatocellular carcinoma, bladder cancer, breast cancer, and colon cancer (<xref rid="B31" ref-type="bibr">31–34</xref>). This exemplifies the pan-cancer impact of specific genes and illustrates the crucial role of CDH1 as a driver gene in cancer progression. DriverDBv4 can help researchers explore the molecular underpinnings of driver genes across different cancer types and evaluate their pan-cancer significance.</p>
    <p>The proteomic analysis in DriverDBv4 enables researchers to explore noteworthy proteins in cancer and addresses the insufficiency of transcript levels for representing protein levels in many scenarios (<xref rid="B35" ref-type="bibr">35</xref>). Researchers can investigate protein abundance distributions, considering various PTMs, and compare them between different pathological stages and mutation states (Figure <xref rid="F2" ref-type="fig">2A</xref>). It has been suggested that mRNA and protein correlation analysis may reveal potential candidates for anticancer therapy (<xref rid="B36" ref-type="bibr">36</xref>). For example, a high correlation between RNA and protein levels in ERBB2 in BRCA (Figure <xref rid="F2" ref-type="fig">2B</xref>, right panel) has been reported with therapeutic opportunities (<xref rid="B10" ref-type="bibr">10</xref>). Moreover, different PTMs, such as phosphorylation at Tyr1068 and Tyr1173 of EGFR, exert multifaceted impacts on cancer therapy outcomes (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>). Although both modifications activate EGFR, the phosphorylation of Tyr1173 in EGFR is affected by more factors, such as mutation, than that of Tyr1068 (<xref rid="B39" ref-type="bibr">39</xref>). This implies that the RNA of EGFR is insufficient to represent the abundance of Tyr1173, resulting in a weaker correlation than Tyr1068, which is not affected by other factors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3C</xref>). These findings demonstrate the importance of investigating the correlations between mRNA and protein/PTMs.</p>
    <p>To accommodate the expanded datasets and new multi-omics integration results, we have redesigned the visualizations to provide a comprehensive summary of the data. In particular, the Gene section features the Multi-Omics Plot (Figure <xref rid="F1" ref-type="fig">1C</xref>, bottom right), which illustrates the overlap between omics across cancer types and helps researchers compare multi-omics features at a glance. The bar charts (Figure <xref rid="F1" ref-type="fig">1C</xref>, top right and bottom left) provide insights into the distribution of omics and cancer types. A Sankey diagram (Figure <xref rid="F1" ref-type="fig">1B</xref>) establishes connections between omics, genes, and biological functions, revealing the top multi-omics features and their functional implications. Our redesigned figures show single-/multi-omics drivers in the heatmap and network plot in the ‘Gene’ section summary (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figures 2B and 3B</xref>). Furthermore, a new ‘Protein’ panel introduces interactive plots that highlight protein abundances (Figure <xref rid="F2" ref-type="fig">2A</xref>) and their corresponding mRNA associations (Figure <xref rid="F2" ref-type="fig">2B</xref>). By incorporating such dynamic visualizations and promoting multi-omics integration, DriverDBv4 enhances the understanding of intricate molecular interactions and provides a vital resource for researchers.</p>
    <p>The novel custom analysis introduced in this updated version enables researchers to unravel complex multi-omics features across patient groups and uncover differences in expression patterns associated with specific clinical features of personal interest. ‘Multi-omics Identification’ allows the exploration of multi-omics feature segregation between groups, enabling the identification of potential driver genes in multi-omics layers, such as the joint influence of ERBB2 and MED1 on her2-positive BRCA progression (<xref rid="B25" ref-type="bibr">25</xref>). In addition, ‘Subgroup Expression Analysis’ delves into comprehensive expression patterns, such as PTTG1 up-regulation in advanced KIRC (<xref rid="B26" ref-type="bibr">26</xref>). These demonstrates that the customized analysis enables researchers to independently validate genes or multi-omics features of interest, thereby improving their investigations with robust insights derived from DriverDBv4.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad1060_Supplemental_File</label>
      <media xlink:href="gkad1060_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We thank to National Center for High-performance Computing (NCHC) for providing computational and storage resources.</p>
    <p><italic toggle="yes">Author contributions</italic>: C.H.L. conducts all analyses and designs the database. Y.L.L. and C.H.L. wrote the manuscript. Y.L.L. and Y.D.W. access clinical features for customized analysis. P.C.S. layouts and designs figures. H.C.L. and M.H.T. design the interactive web interface. W.J.L., F.H.C., C.Y.L. and S.C.W. curated the data. W.C.C. revises the final version of the manuscript.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>The DriverDB database will be continuously maintained and updated. The database is now publicly accessible at <ext-link xlink:href="http://driverdb.bioinfomics.org/" ext-link-type="uri">http://driverdb.bioinfomics.org/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad1060#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Science and Technology Council, Taiwan, R.O.C. [NSTC 112-2311-B-039-001 and NSTC 111-2622-E-039-004]; China Medical University, Taiwan, R.O.C. [CMU112-MF-25, CMU111-MF-72, CMU111-IP-04]; China Medical University Hospital, Taiwan, R.O.C. [DMR-111-075, DMR-112-237, DMR-112-056]; ‘Cancer Biology and Precision Therapeutics Center, China Medical University’ from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (in part). Funding for open access charge: National Science and Technology Council, Taiwan, R.O.C.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vasaikar</surname><given-names>S.V.</given-names></string-name>, <string-name><surname>Straub</surname><given-names>P.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name></person-group><article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>46</volume>:<fpage>D956</fpage>–<lpage>D963</lpage>.</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chandrashekar</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Karthikeyan</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Korla</surname><given-names>P.K.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>H.</given-names></string-name>, <string-name><surname>Shovon</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Athar</surname><given-names>M.</given-names></string-name>, <string-name><surname>Netto</surname><given-names>G.J.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Z.S.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Manne</surname><given-names>U.</given-names></string-name><etal>et al</etal>.</person-group><article-title>UALCAN: an update to the integrated cancer data analysis platform</article-title>. <source>Neoplasia</source>. <year>2022</year>; <volume>25</volume>:<fpage>18</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">35078134</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>I.F.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Fen</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>T.Y.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.W.</given-names></string-name></person-group><article-title>DriverDB: an exome sequencing database for cancer driver gene identification</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D1048</fpage>–<lpage>D1054</lpage>.<pub-id pub-id-type="pmid">24214964</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>S.-H.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>P.-C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.-Y.</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>A.-N.</given-names></string-name>, <string-name><surname>Cho</surname><given-names>Y.-C.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>Y.-L.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>F.-H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.-Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.-C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DriverDBv3: a multi-omics database for cancer driver gene research</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D863</fpage>–<lpage>D870</lpage>.<pub-id pub-id-type="pmid">31701128</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Collisson</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Mills</surname><given-names>G.B.</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Ozenberger</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Ellrott</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shmulevich</surname><given-names>I.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>J.M.</given-names></string-name></person-group><article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat. Genet.</source><year>2013</year>; <volume>45</volume>:<fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hudson</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>W.</given-names></string-name>, <string-name><surname>Artez</surname><given-names>A.</given-names></string-name>, <string-name><surname>Barker</surname><given-names>A.D.</given-names></string-name>, <string-name><surname>Bell</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bernabé</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Bhan</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Calvo</surname><given-names>F.</given-names></string-name>, <string-name><surname>Eerola</surname><given-names>I.</given-names></string-name>, <string-name><surname>Gerhard</surname><given-names>D.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>International network of cancer genome projects</article-title>. <source>Nature</source>. <year>2010</year>; <volume>464</volume>:<fpage>993</fpage>–<lpage>998</lpage>.<pub-id pub-id-type="pmid">20393554</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Alexandrov</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Edmonson</surname><given-names>M.N.</given-names></string-name>, <string-name><surname>Gawad</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Rusch</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Easton</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours</article-title>. <source>Nature</source>. <year>2018</year>; <volume>555</volume>:<fpage>371</fpage>–<lpage>376</lpage>.<pub-id pub-id-type="pmid">29489755</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colaprico</surname><given-names>A.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Olsen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Garofano</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cava</surname><given-names>C.</given-names></string-name>, <string-name><surname>Garolini</surname><given-names>D.</given-names></string-name>, <string-name><surname>Sabedot</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Malta</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Pagnotta</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Castiglioni</surname><given-names>I.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>e71</fpage>.<pub-id pub-id-type="pmid">26704973</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saal</surname><given-names>L.H.</given-names></string-name>, <string-name><surname>Vallon-Christersson</surname><given-names>J.</given-names></string-name>, <string-name><surname>Häkkinen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hegardt</surname><given-names>C.</given-names></string-name>, <string-name><surname>Grabau</surname><given-names>D.</given-names></string-name>, <string-name><surname>Winter</surname><given-names>C.</given-names></string-name>, <string-name><surname>Brueffer</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Reuterswärd</surname><given-names>C.</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine</article-title>. <source>Genome Med.</source><year>2015</year>; <volume>7</volume>:<fpage>20</fpage>.<pub-id pub-id-type="pmid">25722745</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akbani</surname><given-names>R.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>P.K.S.</given-names></string-name>, <string-name><surname>Werner</surname><given-names>H.M.J.</given-names></string-name>, <string-name><surname>Shahmoradgoli</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ju</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.-Y.</given-names></string-name>, <string-name><surname>Yoshihara</surname><given-names>K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A pan-cancer proteomic perspective on The Cancer Genome Atlas</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>3887</fpage>.<pub-id pub-id-type="pmid">24871328</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leiserson</surname><given-names>M.D.M.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>H.-T.</given-names></string-name>, <string-name><surname>Vandin</surname><given-names>F.</given-names></string-name>, <string-name><surname>Raphael</surname><given-names>B.J.</given-names></string-name></person-group><article-title>CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer</article-title>. <source>Genome Biol.</source><year>2015</year>; <volume>16</volume>:<fpage>160</fpage>.<pub-id pub-id-type="pmid">26253137</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hou</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name></person-group><article-title>DawnRank: discovering personalized driver genes in cancer</article-title>. <source>Genome Medicine</source>. <year>2014</year>; <volume>6</volume>:<fpage>56</fpage>.<pub-id pub-id-type="pmid">25177370</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Argelaguet</surname><given-names>R.</given-names></string-name>, <string-name><surname>Arnol</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bredikhin</surname><given-names>D.</given-names></string-name>, <string-name><surname>Deloro</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Velten</surname><given-names>B.</given-names></string-name>, <string-name><surname>Marioni</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Stegle</surname><given-names>O.</given-names></string-name></person-group><article-title>MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data</article-title>. <source>Genome Biol.</source><year>2020</year>; <volume>21</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">32393329</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>A.</given-names></string-name>, <string-name><surname>Shannon</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Gautier</surname><given-names>B.</given-names></string-name>, <string-name><surname>Rohart</surname><given-names>F.</given-names></string-name>, <string-name><surname>Vacher</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tebbutt</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Lê Cao</surname><given-names>K.-A.</given-names></string-name></person-group><article-title>DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays</article-title>. <source>Bioinformatics</source>. <year>2019</year>; <volume>35</volume>:<fpage>3055</fpage>–<lpage>3062</lpage>.<pub-id pub-id-type="pmid">30657866</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bin</surname><given-names>Y.</given-names></string-name></person-group><article-title>DriverSubNet: a novel algorithm for identifying cancer driver genes by subnetwork enrichment analysis</article-title>. <source>Front. Genet.</source><year>2021</year>; <volume>11</volume>:<fpage>607798</fpage>.<pub-id pub-id-type="pmid">33679866</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thévenot</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Roux</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ezan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Junot</surname><given-names>C.</given-names></string-name></person-group><article-title>Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses</article-title>. <source>J. Proteome Res.</source><year>2015</year>; <volume>14</volume>:<fpage>3322</fpage>–<lpage>3335</lpage>.<pub-id pub-id-type="pmid">26088811</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moon</surname><given-names>S.</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>H.</given-names></string-name></person-group><article-title>SDGCCA: supervised deep generalized canonical correlation analysis for multi-omics integration</article-title>. <source>J. Comput. Biol.</source><year>2022</year>; <volume>29</volume>:<fpage>892</fpage>–<lpage>907</lpage>.<pub-id pub-id-type="pmid">35951002</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tenenhaus</surname><given-names>A.</given-names></string-name>, <string-name><surname>Philippe</surname><given-names>C.</given-names></string-name>, <string-name><surname>Guillemot</surname><given-names>V.</given-names></string-name>, <string-name><surname>Le Cao</surname><given-names>K.-A.</given-names></string-name>, <string-name><surname>Grill</surname><given-names>J.</given-names></string-name>, <string-name><surname>Frouin</surname><given-names>V.</given-names></string-name></person-group><article-title>Variable selection for generalized canonical correlation analysis</article-title>. <source>Biostatistics</source>. <year>2014</year>; <volume>15</volume>:<fpage>569</fpage>–<lpage>583</lpage>.<pub-id pub-id-type="pmid">24550197</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Djuric</surname><given-names>U.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>K.H.B.</given-names></string-name>, <string-name><surname>Kao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Batruch</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jevtic</surname><given-names>S.</given-names></string-name>, <string-name><surname>Papaioannou</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Diamandis</surname><given-names>P.</given-names></string-name></person-group><article-title>Defining protein pattern differences among molecular subtypes of diffuse gliomas using mass spectrometry</article-title>. <source>Mol. Cell. Proteomics</source>. <year>2019</year>; <volume>18</volume>:<fpage>2029</fpage>–<lpage>2043</lpage>.<pub-id pub-id-type="pmid">31353322</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Butti</surname><given-names>R.</given-names></string-name>, <string-name><surname>Das</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gunasekaran</surname><given-names>V.P.</given-names></string-name>, <string-name><surname>Yadav</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kundu</surname><given-names>G.C.</given-names></string-name></person-group><article-title>Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges</article-title>. <source>Mol. Cancer</source>. <year>2018</year>; <volume>17</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">29455658</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Dorsey</surname><given-names>T.H.</given-names></string-name>, <string-name><surname>Prieto</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.W.</given-names></string-name>, <string-name><surname>Ruppin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Veenstra</surname><given-names>T.D.</given-names></string-name>, <string-name><surname>Ambs</surname><given-names>S.</given-names></string-name></person-group><article-title>Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival</article-title>. <source>Genome Medicine</source>. <year>2018</year>; <volume>10</volume>:<fpage>94</fpage>.<pub-id pub-id-type="pmid">30501643</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>ten Hoorn</surname><given-names>S.</given-names></string-name>, <string-name><surname>de Back</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Sommeijer</surname><given-names>D.W.</given-names></string-name>, <string-name><surname>Vermeulen</surname><given-names>L.</given-names></string-name></person-group><article-title>Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta analysis</article-title>. <source>J. Natl. Cancer Inst.</source><year>2021</year>; <volume>114</volume>:<fpage>503</fpage>–<lpage>516</lpage>.</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>F.</given-names></string-name>, <string-name><surname>Guan</surname><given-names>M.</given-names></string-name></person-group><article-title>Delving into the heterogeneity of different breast cancer subtypes and the prognostic models utilizing scRNA-Seq and bulk RNA-Seq</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>:<fpage>9936</fpage>.<pub-id pub-id-type="pmid">36077333</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>He</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Liao</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ren</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma</article-title>. <source>Clin. Cancer Res.</source><year>2022</year>; <volume>28</volume>:<fpage>1896</fpage>–<lpage>1910</lpage>.<pub-id pub-id-type="pmid">34526363</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Leonard</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Mahmoud</surname><given-names>C.</given-names></string-name>, <string-name><surname>Khan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lower</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><article-title>HER2-driven breast tumorigenesis relies upon interactions of the estrogen receptor with coactivator MED1</article-title>. <source>Cancer Res.</source><year>2018</year>; <volume>78</volume>:<fpage>422</fpage>–<lpage>435</lpage>.<pub-id pub-id-type="pmid">29187405</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gui</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>P.</given-names></string-name></person-group><article-title>Overexpressing PTTG family genes predict poor prognosis in kidney renal clear cell carcinoma</article-title>. <source>World J. Surg. Oncol.</source><year>2021</year>; <volume>19</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">33845847</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Kuang</surname><given-names>X.Y.</given-names></string-name>, <string-name><surname>Zuo</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>F.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Z.G.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>S.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>1357</fpage>.<pub-id pub-id-type="pmid">29636477</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kołodziej</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nicoś</surname><given-names>M.</given-names></string-name>, <string-name><surname>Krawczyk</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Bogucki</surname><given-names>J.</given-names></string-name>, <string-name><surname>Karczmarczyk</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zalewski</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kubrak</surname><given-names>T.</given-names></string-name>, <string-name><surname>Kołodziej</surname><given-names>E.</given-names></string-name>, <string-name><surname>Makuch-Kocka</surname><given-names>A.</given-names></string-name>, <string-name><surname>Madej-Czerwonka</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The correlation of mutations and expressions of genes within the PI3K/Akt/mTOR pathway in breast cancer - a preliminary study</article-title>. <source>Int. J. Mol. Sci.</source><year>2021</year>; <volume>22</volume>:<fpage>2061</fpage>.<pub-id pub-id-type="pmid">33669698</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cizkova</surname><given-names>M.</given-names></string-name>, <string-name><surname>Vacher</surname><given-names>S.</given-names></string-name>, <string-name><surname>Meseure</surname><given-names>D.</given-names></string-name>, <string-name><surname>Trassard</surname><given-names>M.</given-names></string-name>, <string-name><surname>Susini</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mlcuchova</surname><given-names>D.</given-names></string-name>, <string-name><surname>Callens</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rouleau</surname><given-names>E.</given-names></string-name>, <string-name><surname>Spyratos</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lidereau</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PIK3R1 underexpression is an independent prognostic marker in breast cancer</article-title>. <source>BMC Cancer</source>. <year>2013</year>; <volume>13</volume>:<fpage>545</fpage>.<pub-id pub-id-type="pmid">24229379</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shenoy</surname><given-names>S.</given-names></string-name></person-group><article-title>CDH1 (E-Cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management</article-title>. <source>Cancer Manag. Res.</source><year>2019</year>; <volume>11</volume>:<fpage>10477</fpage>–<lpage>10486</lpage>.<pub-id pub-id-type="pmid">31853199</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname><given-names>T.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>L.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>B.</given-names></string-name>, <string-name><surname>He</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Han</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y.</given-names></string-name></person-group><article-title>CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration</article-title>. <source>BMC Urol.</source><year>2022</year>; <volume>22</volume>:<fpage>156</fpage>.<pub-id pub-id-type="pmid">36131343</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pomo</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Gullapalli</surname><given-names>R.R.</given-names></string-name></person-group><article-title>Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics</article-title>. <source>Cancer Cell Int.</source><year>2016</year>; <volume>16</volume>:<fpage>44</fpage>.<pub-id pub-id-type="pmid">27303212</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>F.M.</given-names></string-name>, <string-name><surname>McKee</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Rajpar</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Evans</surname><given-names>D.G.</given-names></string-name>, <string-name><surname>Jankowski</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>McKeown</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sanders</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Maher</surname><given-names>E.R.</given-names></string-name></person-group><article-title>Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer</article-title>. <source>Hum. Mol. Genet.</source><year>1999</year>; <volume>8</volume>:<fpage>607</fpage>–<lpage>610</lpage>.<pub-id pub-id-type="pmid">10072428</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname><given-names>D.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pei</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>T.</given-names></string-name></person-group><article-title>The potential role of CDH1 as an oncogene combined with related miRNAs and their diagnostic value in breast cancer</article-title>. <source>Front. Endocrinol. (Lausanne)</source>. <year>2022</year>; <volume>13</volume>:<fpage>916469</fpage>.<pub-id pub-id-type="pmid">35784532</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Beyer</surname><given-names>A.</given-names></string-name>, <string-name><surname>Aebersold</surname><given-names>R.</given-names></string-name></person-group><article-title>On the dependency of cellular protein levels on mRNA abundance</article-title>. <source>Cell</source>. <year>2016</year>; <volume>165</volume>:<fpage>535</fpage>–<lpage>550</lpage>.<pub-id pub-id-type="pmid">27104977</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andrieux</surname><given-names>G.</given-names></string-name>, <string-name><surname>Chakraborty</surname><given-names>S.</given-names></string-name>, <string-name><surname>Das</surname><given-names>T.</given-names></string-name>, <string-name><surname>Boerries</surname><given-names>M.</given-names></string-name></person-group><article-title>Alteration of proteotranscriptomic landscape reveals the transcriptional regulatory circuits controlling key-signaling pathways and metabolic reprogramming during tumor evolution</article-title>. <source>Front. Cell Dev. Biol.</source><year>2020</year>; <volume>8</volume>:<fpage>586479</fpage>.<pub-id pub-id-type="pmid">33384992</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Duan</surname><given-names>J.</given-names></string-name>, <string-name><surname>An</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>the Key Laboratory of</surname><given-names>C.</given-names></string-name>, <string-name><surname>Translational</surname><given-names>R.</given-names></string-name></person-group><article-title>Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR</article-title>. <source>J. Exp. Clin. Cancer Res.</source><year>2012</year>; <volume>31</volume>:<fpage>65</fpage>.<pub-id pub-id-type="pmid">22901364</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sette</surname><given-names>G.</given-names></string-name>, <string-name><surname>Salvati</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mottolese</surname><given-names>M.</given-names></string-name>, <string-name><surname>Visca</surname><given-names>P.</given-names></string-name>, <string-name><surname>Gallo</surname><given-names>E.</given-names></string-name>, <string-name><surname>Fecchi</surname><given-names>K.</given-names></string-name>, <string-name><surname>Pilozzi</surname><given-names>E.</given-names></string-name>, <string-name><surname>Duranti</surname><given-names>E.</given-names></string-name>, <string-name><surname>Policicchio</surname><given-names>E.</given-names></string-name>, <string-name><surname>Tartaglia</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer</article-title>. <source>Cell Death. Dis.</source><year>2015</year>; <volume>6</volume>:<fpage>e1850</fpage>.<pub-id pub-id-type="pmid">26247735</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zimmer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kahl</surname><given-names>P.</given-names></string-name>, <string-name><surname>Buhl</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Steiner</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wardelmann</surname><given-names>E.</given-names></string-name>, <string-name><surname>Merkelbach-Bruse</surname><given-names>S.</given-names></string-name>, <string-name><surname>Buettner</surname><given-names>R.</given-names></string-name>, <string-name><surname>Heukamp</surname><given-names>L.C.</given-names></string-name></person-group><article-title>Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling</article-title>. <source>J. Cancer Res. Clin. Oncol.</source><year>2009</year>; <volume>135</volume>:<fpage>723</fpage>–<lpage>730</lpage>.<pub-id pub-id-type="pmid">19002495</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">Nucleic Acids Res</journal-id>
    <journal-id journal-id-type="publisher-id">nar</journal-id>
    <journal-title-group>
      <journal-title>Nucleic Acids Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0305-1048</issn>
    <issn pub-type="epub">1362-4962</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10767848</article-id>
    <article-id pub-id-type="pmid">37956338</article-id>
    <article-id pub-id-type="doi">10.1093/nar/gkad1060</article-id>
    <article-id pub-id-type="publisher-id">gkad1060</article-id>
    <article-categories>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00010</subject>
      </subj-group>
      <subj-group subj-group-type="heading">
        <subject>Database Issue</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>DriverDBv4: a multi-omics integration database for cancer driver gene research</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Chia-Hsin</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lai</surname>
          <given-names>Yo-Liang</given-names>
        </name>
        <aff><institution>Department of Radiation Oncology, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="FN1" ref-type="author-notes"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Shen</surname>
          <given-names>Pei-Chun</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Liu</surname>
          <given-names>Hsiu-Cheng</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Tsai</surname>
          <given-names>Meng-Hsin</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Yu-De</given-names>
        </name>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Department of Urology, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Lin</surname>
          <given-names>Wen-Jen</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>School of Medicine, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Chen</surname>
          <given-names>Fang-Hsin</given-names>
        </name>
        <aff><institution>Institute of Nuclear Engineering and Science, National Tsing Hua University</institution>, <addr-line>Hsinchu 300044</addr-line>, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Li</surname>
          <given-names>Chia-Yang</given-names>
        </name>
        <aff><institution>Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University</institution>, Kaohsiung 80708, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wang</surname>
          <given-names>Shu-Chi</given-names>
        </name>
        <aff><institution>Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University</institution>, Kaohsiung 80708, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hung</surname>
          <given-names>Mien-Chie</given-names>
        </name>
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Institute of Biochemistry and Molecular Biology, China Medical University</institution>, <addr-line>Taichung 404328</addr-line>, <country country="TW">Taiwan</country></aff>
        <aff><institution>Molecular Medicine Center, China Medical University Hospital, China Medical University</institution>, <addr-line>Taichung 404328</addr-line>, <country country="TW">Taiwan</country></aff>
        <aff><institution>Department of Biotechnology, Asia University</institution>, <addr-line>Taichung 413305</addr-line>, <country country="TW">Taiwan</country></aff>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1229-4857</contrib-id>
        <name>
          <surname>Cheng</surname>
          <given-names>Wei-Chung</given-names>
        </name>
        <!--cwc0702@gmail.com-->
        <aff><institution>Cancer Biology and Precision Therapeutics Center, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>Graduate Institute of Biomedical Sciences, China Medical University</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <aff><institution>The Ph.D. program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica</institution>, Taichung 404328, <country country="TW">Taiwan</country></aff>
        <xref rid="COR1" ref-type="corresp"/>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR1">To whom correspondence should be addressed. Tel: +886 4 2205 2121 (Ext 7820); Fax: +886 4 2233 3496; Email: <email>cwc0702@gmail.com</email></corresp>
      <fn id="FN1">
        <p>The authors wish it to be known that, in their opinion, the first two authors should be regarded as Joint First Authors.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>1</month>
      <year>2024</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2023-11-13">
      <day>13</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>13</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <volume>52</volume>
    <issue>D1</issue>
    <fpage>D1246</fpage>
    <lpage>D1252</lpage>
    <history>
      <date date-type="accepted">
        <day>25</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>10</month>
        <year>2023</year>
      </date>
      <date date-type="received">
        <day>14</day>
        <month>9</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research.</copyright-statement>
      <copyright-year>2024</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email></license-p>
      </license>
    </permissions>
    <self-uri xlink:href="gkad1060.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>Advancements in high-throughput technology offer researchers an extensive range of multi-omics data that provide deep insights into the complex landscape of cancer biology. However, traditional statistical models and databases are inadequate to interpret these high-dimensional data within a multi-omics framework. To address this limitation, we introduce DriverDBv4, an updated iteration of the DriverDB cancer driver gene database (<ext-link xlink:href="http://driverdb.bioinfomics.org/" ext-link-type="uri">http://driverdb.bioinfomics.org/</ext-link>). This updated version offers several significant enhancements: (i) an increase in the number of cohorts from 33 to 70, encompassing approximately 24 000 samples; (ii) inclusion of proteomics data, augmenting the existing types of omics data and thus expanding the analytical scope; (iii) implementation of multiple multi-omics algorithms for identification of cancer drivers; (iv) new visualization features designed to succinctly summarize high-context data and redesigned existing sections to accommodate the increased volume of datasets and (v) two new functions in Customized Analysis, specifically designed for multi-omics driver identification and subgroup expression analysis. DriverDBv4 facilitates comprehensive interpretation of multi-omics data across diverse cancer types, thereby enriching the understanding of cancer heterogeneity and aiding in the development of personalized clinical approaches. The database is designed to foster a more nuanced understanding of the multi-faceted nature of cancer.</p>
    </abstract>
    <abstract abstract-type="graphical">
      <title>Graphical Abstract</title>
      <p>
        <fig position="float" id="ga1">
          <label>Graphical Abstract</label>
          <graphic xlink:href="gkad1060figgra1" position="float"/>
        </fig>
      </p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Science and Technology Council</institution>
            <institution-id institution-id-type="DOI">10.13039/100020595</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>NSTC 112-2311-B-039-001</award-id>
        <award-id>NSTC 111-2622-E-039-004</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100007300</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>CMU112-MF-25</award-id>
        <award-id>CMU111-MF-72</award-id>
        <award-id>CMU111-IP-04</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University Hospital</institution>
            <institution-id institution-id-type="DOI">10.13039/501100004391</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>DMR-111-075</award-id>
        <award-id>DMR-112-237</award-id>
        <award-id>DMR-112-056</award-id>
      </award-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>China Medical University</institution>
            <institution-id institution-id-type="DOI">10.13039/501100007300</institution-id>
          </institution-wrap>
        </funding-source>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="7"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec sec-type="intro" id="SEC1">
    <title>Introduction</title>
    <p>High-throughput technology empowers the generation of comprehensive data across various omics layers and offers unparalleled insights into the molecular intricacies of cancer. Arising from perturbations in multiple omics layers, cancer necessitates a holistic approach for a broader understanding of the disease. The integration of multi-omics data provides a panoramic view of biological systems, enabling the exploration of complex relationships and identification of the different manifestations of dysregulation underlying cancer. Furthermore, the deciphering of multi-omics data promises a deeper understanding of the molecular landscape of cancer and its broader implications. Consequently, the integration of multi-omics is attracting increasing attention in cancer research and is stimulating an approach that spans multiple biological scales and fosters new insights into oncology.</p>
    <p>Several multi-omics databases or web servers, such as LinkedOmics (<xref rid="B1" ref-type="bibr">1</xref>) and UALCAN (<xref rid="B2" ref-type="bibr">2</xref>), have used statistical models like Pearson/Spearman correlation and the Kaplan–Meier method to analyze correlations between omics or between clinical features. However, such canonical methods can only attempt pairwise integration of omics since they are not designed to handle data at higher dimensions. In recent years, advancements in mathematical methods, such as matrix deconvolution, machine learning, and network approaches, have significantly enhanced multi-omics integration technology. While these novel methodologies have the potential to offer a broad and thorough understanding of cancer, which involves numerous factors that interact dynamically, application of multi-omics integration methods to decipher cancer drivers is still necessary and remains inadequate.</p>
    <p>DriverDB is a cancer driver gene database that has been in use since 2014 (<xref rid="B3" ref-type="bibr">3</xref>,<xref rid="B4" ref-type="bibr">4</xref>). The most recent release, DriverDBv4, has significantly enhanced capabilities and expanded datasets. In addition, DriverDBv4 has incorporated proteome data, allowing a deeper understanding of the molecular landscape. The database employs various approaches to comprehensively dissect cancer drivers by exploiting multi-omics integration methodologies. The user interface has been carefully improved to include new visualization plots that accurately show the integration of multi-omics data. Two new functions have been added to the ‘Customized Analysis’ section. Overall, DriverDBv4 allows researchers to explore the complex relationships between cancers and driver genes.</p>
  </sec>
  <sec sec-type="materials|methods" id="SEC2">
    <title>Materials and methods</title>
    <sec id="SEC2-1">
      <title>Data collection</title>
      <p>The updated DriverDBv4 has 25 509 cancer patient samples across six types of omics. In addition to 33 cancer types with 10 914 patients from The Cancer Genome Atlas Program (TCGA) (<xref rid="B5" ref-type="bibr">5</xref>), 37 cancer types with &gt;14 595 patients from the International Cancer Genome Consortium (ICGC) (<xref rid="B6" ref-type="bibr">6</xref>), Therapeutically Applicable Research to Generate Effective Targets (TARGET) (<xref rid="B7" ref-type="bibr">7</xref>), and The Sweden Cancerome Analysis Network-Breast (SCAN-B) (<xref rid="B9" ref-type="bibr">9</xref>) were included in the updated DriverDBv4.</p>
      <p>Omics data and corresponding clinical data from TCGA, ICGC, and TARGET were obtained through TCGAbiolinks (<xref rid="B8" ref-type="bibr">8</xref>). Data on gene expression, along with corresponding clinical features of SCAN-B, were curated from GSE81540 and their original paper (<xref rid="B9" ref-type="bibr">9</xref>) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>). Molecular subgroup classifications of patients, such as lumina A and lumina B for BRCA, were obtained from TCGAbiolinks (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 2</xref>) in order to help users to define patient groups in ‘Customized Analysis’.</p>
      <p>Protein abundances of all 32 cancer types released from TCGA were assessed by the reverse phase protein array which was designed to quantify both abundances of total protein and protein with post-translational modifications (<xref rid="B10" ref-type="bibr">10</xref>). TCGAbiolinks provided the protein abundance values without further processing as the expression values had been normalized.</p>
      <p>Patients’ clinical features were selected and curated by oncologists and records without clinical information, such as the submission date, were removed. Furthermore, records with duplicated information were merged according to oncologists’ suggestions; for example, her2 status was judged based on immunohistochemistry status and fluorescence <italic toggle="yes">in situ</italic> hybridization outcomes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>).</p>
    </sec>
    <sec id="SEC2-2">
      <title>Multi-omics integration algorithm</title>
      <p>DriverDBv4 includes eight multi-omics integration algorithms, CoMEt (<xref rid="B11" ref-type="bibr">11</xref>), DawnRank (<xref rid="B12" ref-type="bibr">12</xref>), MOFA (<xref rid="B13" ref-type="bibr">13</xref>), DIABLO (<xref rid="B14" ref-type="bibr">14</xref>), DriverSubNet (<xref rid="B15" ref-type="bibr">15</xref>), OPLSDA (<xref rid="B16" ref-type="bibr">16</xref>), SDGCCA (<xref rid="B17" ref-type="bibr">17</xref>) and SGCCA (<xref rid="B18" ref-type="bibr">18</xref>), which are used to interpret multi-omics driver features. A matrix deconvolution method, e.g. MOFA, was used to identify the multi-omics factors that capture most of the variation in each omics dataset. Canonical correlation analysis methods, such as SGCCA, SDGCCA and DIABLO, performed linear transformations of each omics dataset to achieve the highest correlation between the data from the multiple omics datasets and clinical data. Linear discriminant analysis methods, such as OPLSDA, identified a linear combination of features from multi-omics data that separated two classes. Network approaches, such as DawnRank and DriverSubNet, integrated different omics data from heterogeneous layers into a single network or sub-network. A statistical approach, CoMEt, was used to identify combinations of mutually exclusive changes across omics. The multi-omics analysis was conducted on datasets derived from four different types of omics data, each with a sample size exceeding five. Further information on each algorithm is provided in supplementary methods and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 3</xref>.</p>
    </sec>
  </sec>
  <sec sec-type="results" id="SEC3">
    <title>Results</title>
    <p>DriverDBv4 offers three sections, ‘Cancer,’ ‘Gene’ and ‘Customized analysis’, to analyze several molecular features of cancer. New functions have been added to the three sections to promote the integration of individual omics datasets, enabling researchers to investigate the intricate interactions between multiple omics layers.</p>
    <sec id="SEC3-1">
      <title>Cancer</title>
      <p>A new panel, termed ‘multi-omics,’ has been added specifically to integrate multi-omics data and offers a fresh perspective on studying cancer hallmark genes (Figure <xref rid="F1" ref-type="fig">1A</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2A</xref>). This panel allows researchers to not only explore the contributions of various omics to the driver genes but also simultaneously link biological functions to the specific cancer of interest (Figure <xref rid="F1" ref-type="fig">1B</xref>). Furthermore, this new information is also added to the pre-existing summary page to visualize the intricate network connections between multi-omics driver genes (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2B</xref>).</p>
      <fig position="float" id="F1">
        <label>Figure 1.</label>
        <caption>
          <p>Multi-omics integration in DriverDBv4. (<bold>A</bold>) Genes identified by multi-omics integration algorithms are summarized. The distribution of top 30 genes among different omics layers are shown in a heatmap (upper panel) and are ranked by the number of tools which identify the gene in a dodged bar chart (bottom panel). The features were ranked according to both the number of omics and the number of tools utilized to identify these drivers. (<bold>B</bold>) A Sankey diagram is used to demonstrate the relationship between genes in multi-omics and corresponding biological functions. (<bold>C</bold>) A multi-omics plot depicts the interplay of multiple omics characteristics of a specific gene among several cancers. The black solid dot represents the gene that is identified by at least one multi-omics integration algorithm and linked together by a black line (right-bottom panel). The distribution of the number of a gene identified by algorithms is depicted in a bar chart according to the cancer axis (upper-right panel) or the omics axis (bottom-left panel), respectively.</p>
        </caption>
        <graphic xlink:href="gkad1060fig1" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-2">
      <title>Gene</title>
      <p>Genes that exhibit driver features in various cancer types are of significant value for allocating crucial biological functions shared by cancers. The new "multi-omics" panel in the Gene section evaluates not only the importance of a gene as a multi-omics driver but also how vital the gene is for various cancer types (Figure <xref rid="F1" ref-type="fig">1C</xref>, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3A</xref>). The integration of multi-omics data analysis through the Gene section empowers researchers to explore multi-omics drivers and evaluate them across several cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3B</xref>).</p>
      <p>Protein abundance and post-translational modifications (PTMs), such as RTK phosphorylation, have previously been established as significant factors of cancer heterogeneity. These modifications have been found to correlate with patient survival (<xref rid="B19" ref-type="bibr">19</xref>,<xref rid="B20" ref-type="bibr">20</xref>). In the new ‘Protein’ panel, DriverDBv4 assists researchers to identify differences in protein abundance, including various PTMs, between several cancers and gain a comprehensive understanding of cancer heterogeneity at the proteomic level (Figure <xref rid="F2" ref-type="fig">2A</xref>). Researchers can also evaluate the protein at different tumor stages or mutation statuses. In addition, enrichment of highly correlated transcript and protein levels is associated with reduced patient survival and aggressive disease (<xref rid="B21" ref-type="bibr">21</xref>). To help researchers explore such <italic toggle="yes">cis-</italic>regulation, DriverDBv4 analyzes transcript–protein pairs and summarizes results to provide a pan-cancer view with detailed information (Figure <xref rid="F2" ref-type="fig">2B</xref>).</p>
      <fig position="float" id="F2">
        <label>Figure 2.</label>
        <caption>
          <p>Protein analysis in DriverDBv4. (<bold>A</bold>) The protein abundance distribution among various cancer types is depicted in a box plot stratified by the tumor stage or the mutation status (left panel). The detailed distribution in a specific cancer can also be explored (right panel). (<bold>B</bold>) Correlation coefficients between protein and RNA expression of several cancer types are summarized in a bar chart (left panel). Different PTMs, such as phosphorylation on different tyrosine sites (pY1068 and pY1173) of EGFR, are depicted in different colors for visualization and the statistical analysis result is shown in a dot plot (right panel).</p>
        </caption>
        <graphic xlink:href="gkad1060fig2" position="float"/>
      </fig>
    </sec>
    <sec id="SEC3-3">
      <title>Customized analysis</title>
      <p>Different subtypes of the same cancer class usually vary in drug response and survival risk (<xref rid="B22" ref-type="bibr">22</xref>). Therefore, identifying multi-omics hallmarks of different cancer subtypes is crucial for personalized clinical approaches (<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>). To address this issue, DriverDBv4 has developed two new functions, ‘Multi-omics Driver Analysis’ and ‘Subgroup Expression Analysis,’ which allow researchers to analyze the features differing between groups. The ‘Multi-omics Driver Analysis’ function aims to uncover underlying differences in multi-omics between groups of cancer patients. A compelling example is the exploration of her2-positive breast cancer-associated multi-omics features by contrasting her2-positive and her2-negative patients in BRCA-TCGA, which led to the identification of key her2-related genes, such as ERBB2 and MED1, known to jointly influence her2-positive tumor progression (Figure <xref rid="F1" ref-type="fig">1A</xref>, bottom) (<xref rid="B25" ref-type="bibr">25</xref>). The other function, ‘Subgroup Expression Analysis’, examines differences in gene expression in patients with distinct clinical features, such as tumor neoplasm grade. For example, the pronounced variability in PTTG1 expression between different neoplasm grades in KIRC-TCGA (Figure <xref rid="F3" ref-type="fig">3</xref>). The upregulation of PTTG1 in advanced stages, as well as its elevation compared to its level in normal tissue, supports previous findings (<xref rid="B26" ref-type="bibr">26</xref>).</p>
      <fig position="float" id="F3">
        <label>Figure 3.</label>
        <caption>
          <p>An example of subgroup expression analysis in customized analysis. This violin plot showcases the differential expression between user-defined subgroups based on tumor neoplasm histological grades. Analysis includes patients from the TCGA-KIRC cohort with recorded tumor histological grades. Grades G1 through G4 correspond to neoplasm histological grades 1 to 4, respectively. When available, the normal tissue (NT) is also evaluated. Levels of significance are denoted as follows: * (<italic toggle="yes">P</italic> &lt; 0.05), ** (<italic toggle="yes">P</italic> &lt; 0.01), *** (<italic toggle="yes">P</italic> &lt; 0.001) and **** (<italic toggle="yes">P</italic> &lt; 0.0001).</p>
        </caption>
        <graphic xlink:href="gkad1060fig3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="discussion" id="SEC4">
    <title>Discussion</title>
    <p>DriverDBv4 uses various multi-omics integration algorithms to identify drivers in the complex landscape of cancer and presents these drivers with remarkable clarity, making them easily understandable to the scientific community. Apart from exploring pairwise correlations of omics (such as the information provided by DriverDBv3, LinkedOmics, and UALCAN), DriverDBv4 clarifies intricate driver relationships between multiple omics datasets to provide new insights simultaneously. Researchers can explore multi-omics factors along two axes, ‘Cancer’ and ‘Gene’, according to their specific research requirements. ‘Customized Analysis’ can empower researchers to conduct personalized multi-omics analyses regardless of their programming skills. These advancements in DriverDBv4 are likely to significantly support researchers deciphering the complexities of cancer.</p>
    <p>Several cancer driver databases have previously been published, including IntOGen (<xref rid="B27" ref-type="bibr">27</xref>), OncoVar (<xref rid="B28" ref-type="bibr">28</xref>), and our earlier version, DriverDBv3 (refer to <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>). OncoVar identifies driver genes from the perspective of positive selection in cancer by linking mutation drivers to pathways to analyze potential underlying mechanisms. IntOGen examines various mutation properties and identifies driver genes from the perspective of positive selection in cancer. As shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table 4</xref>, DriverDBv4 expanded a broader range of datasets, incorporated proteomics data, two additional customized analyses, and provided an analysis of multi-omics integration. In DriverDBv3, we evaluated single-omics drivers based on a combination of data from multiple omics sources, as for the methylation driver based on data from both methylation and expression. By incorporating several multi-omics integration algorithms into DriverDBv4, we integrated these drivers defined in DriverDBv3 in a systematic manner to identify potential multi-omics drivers, such as ERBB2 and MED1, which are known to jointly influence the progression of her2-positive tumors (see Figure <xref rid="F1" ref-type="fig">1A</xref>).</p>
    <p>The ‘Cancer’ section of DriverDBv4 enables researchers to identify the complex characteristics of different types of cancer. For example, <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 4A</xref> and Figure <xref rid="F1" ref-type="fig">1B</xref> show the multi-omics drivers in breast cancer. The dual impact of the major gene, PIK3R1, on cancer progression is manifested through both mutational and transcriptional layers (<xref rid="B27" ref-type="bibr">27</xref>,<xref rid="B28" ref-type="bibr">28</xref>). The underexpression of PIK3R1 has been reported as a useful prognostic marker of breast cancer, highlighting its diverse role in disease progression (<xref rid="B29" ref-type="bibr">29</xref>). This emphasizes DriverDBv4’s potential for helping researchers uncover cancer's multidimensional nature.</p>
    <p>The ‘Gene’ section helps researchers explore the molecular properties of a specific driver gene and identify its significance for different cancer types. For example, downregulation of expression or loss-of-function mutations of CDH1 (E-cadherin) may disrupt the maintenance of cell adhesion, cell polarity, and epithelial–mesenchymal transition, thus contributing to invasive tumor behavior (<xref rid="B30" ref-type="bibr">30</xref>). In DriverDBv4, CDH1 is identified as a multi-omics driver in several cancer types (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 5</xref>), including hepatocellular carcinoma, bladder cancer, breast cancer, and colon cancer (<xref rid="B31" ref-type="bibr">31–34</xref>). This exemplifies the pan-cancer impact of specific genes and illustrates the crucial role of CDH1 as a driver gene in cancer progression. DriverDBv4 can help researchers explore the molecular underpinnings of driver genes across different cancer types and evaluate their pan-cancer significance.</p>
    <p>The proteomic analysis in DriverDBv4 enables researchers to explore noteworthy proteins in cancer and addresses the insufficiency of transcript levels for representing protein levels in many scenarios (<xref rid="B35" ref-type="bibr">35</xref>). Researchers can investigate protein abundance distributions, considering various PTMs, and compare them between different pathological stages and mutation states (Figure <xref rid="F2" ref-type="fig">2A</xref>). It has been suggested that mRNA and protein correlation analysis may reveal potential candidates for anticancer therapy (<xref rid="B36" ref-type="bibr">36</xref>). For example, a high correlation between RNA and protein levels in ERBB2 in BRCA (Figure <xref rid="F2" ref-type="fig">2B</xref>, right panel) has been reported with therapeutic opportunities (<xref rid="B10" ref-type="bibr">10</xref>). Moreover, different PTMs, such as phosphorylation at Tyr1068 and Tyr1173 of EGFR, exert multifaceted impacts on cancer therapy outcomes (<xref rid="B37" ref-type="bibr">37</xref>,<xref rid="B38" ref-type="bibr">38</xref>). Although both modifications activate EGFR, the phosphorylation of Tyr1173 in EGFR is affected by more factors, such as mutation, than that of Tyr1068 (<xref rid="B39" ref-type="bibr">39</xref>). This implies that the RNA of EGFR is insufficient to represent the abundance of Tyr1173, resulting in a weaker correlation than Tyr1068, which is not affected by other factors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3C</xref>). These findings demonstrate the importance of investigating the correlations between mRNA and protein/PTMs.</p>
    <p>To accommodate the expanded datasets and new multi-omics integration results, we have redesigned the visualizations to provide a comprehensive summary of the data. In particular, the Gene section features the Multi-Omics Plot (Figure <xref rid="F1" ref-type="fig">1C</xref>, bottom right), which illustrates the overlap between omics across cancer types and helps researchers compare multi-omics features at a glance. The bar charts (Figure <xref rid="F1" ref-type="fig">1C</xref>, top right and bottom left) provide insights into the distribution of omics and cancer types. A Sankey diagram (Figure <xref rid="F1" ref-type="fig">1B</xref>) establishes connections between omics, genes, and biological functions, revealing the top multi-omics features and their functional implications. Our redesigned figures show single-/multi-omics drivers in the heatmap and network plot in the ‘Gene’ section summary (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figures 2B and 3B</xref>). Furthermore, a new ‘Protein’ panel introduces interactive plots that highlight protein abundances (Figure <xref rid="F2" ref-type="fig">2A</xref>) and their corresponding mRNA associations (Figure <xref rid="F2" ref-type="fig">2B</xref>). By incorporating such dynamic visualizations and promoting multi-omics integration, DriverDBv4 enhances the understanding of intricate molecular interactions and provides a vital resource for researchers.</p>
    <p>The novel custom analysis introduced in this updated version enables researchers to unravel complex multi-omics features across patient groups and uncover differences in expression patterns associated with specific clinical features of personal interest. ‘Multi-omics Identification’ allows the exploration of multi-omics feature segregation between groups, enabling the identification of potential driver genes in multi-omics layers, such as the joint influence of ERBB2 and MED1 on her2-positive BRCA progression (<xref rid="B25" ref-type="bibr">25</xref>). In addition, ‘Subgroup Expression Analysis’ delves into comprehensive expression patterns, such as PTTG1 up-regulation in advanced KIRC (<xref rid="B26" ref-type="bibr">26</xref>). These demonstrates that the customized analysis enables researchers to independently validate genes or multi-omics features of interest, thereby improving their investigations with robust insights derived from DriverDBv4.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>gkad1060_Supplemental_File</label>
      <media xlink:href="gkad1060_supplemental_file.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="ACK1">
    <title>Acknowledgements</title>
    <p>We thank to National Center for High-performance Computing (NCHC) for providing computational and storage resources.</p>
    <p><italic toggle="yes">Author contributions</italic>: C.H.L. conducts all analyses and designs the database. Y.L.L. and C.H.L. wrote the manuscript. Y.L.L. and Y.D.W. access clinical features for customized analysis. P.C.S. layouts and designs figures. H.C.L. and M.H.T. design the interactive web interface. W.J.L., F.H.C., C.Y.L. and S.C.W. curated the data. W.C.C. revises the final version of the manuscript.</p>
  </ack>
  <sec sec-type="data-availability" id="SEC5">
    <title>Data availability</title>
    <p>The DriverDB database will be continuously maintained and updated. The database is now publicly accessible at <ext-link xlink:href="http://driverdb.bioinfomics.org/" ext-link-type="uri">http://driverdb.bioinfomics.org/</ext-link>.</p>
  </sec>
  <sec id="SEC6">
    <title>Supplementary data</title>
    <p><ext-link xlink:href="https://academic.oup.com/nar/article-lookup/doi/10.1093/nar/gkad1060#supplementary-data" ext-link-type="uri">Supplementary Data</ext-link> are available at NAR Online.</p>
  </sec>
  <sec id="SEC7">
    <title>Funding</title>
    <p>National Science and Technology Council, Taiwan, R.O.C. [NSTC 112-2311-B-039-001 and NSTC 111-2622-E-039-004]; China Medical University, Taiwan, R.O.C. [CMU112-MF-25, CMU111-MF-72, CMU111-IP-04]; China Medical University Hospital, Taiwan, R.O.C. [DMR-111-075, DMR-112-237, DMR-112-056]; ‘Cancer Biology and Precision Therapeutics Center, China Medical University’ from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan (in part). Funding for open access charge: National Science and Technology Council, Taiwan, R.O.C.</p>
    <p><italic toggle="yes">Conflict of interest statement</italic>. None declared.</p>
  </sec>
  <ref-list id="REF1">
    <title>References</title>
    <ref id="B1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vasaikar</surname><given-names>S.V.</given-names></string-name>, <string-name><surname>Straub</surname><given-names>P.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>B.</given-names></string-name></person-group><article-title>LinkedOmics: analyzing multi-omics data within and across 32 cancer types</article-title>. <source>Nucleic Acids Res.</source><year>2017</year>; <volume>46</volume>:<fpage>D956</fpage>–<lpage>D963</lpage>.</mixed-citation>
    </ref>
    <ref id="B2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chandrashekar</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Karthikeyan</surname><given-names>S.K.</given-names></string-name>, <string-name><surname>Korla</surname><given-names>P.K.</given-names></string-name>, <string-name><surname>Patel</surname><given-names>H.</given-names></string-name>, <string-name><surname>Shovon</surname><given-names>A.R.</given-names></string-name>, <string-name><surname>Athar</surname><given-names>M.</given-names></string-name>, <string-name><surname>Netto</surname><given-names>G.J.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>Z.S.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>S.</given-names></string-name>, <string-name><surname>Manne</surname><given-names>U.</given-names></string-name><etal>et al</etal>.</person-group><article-title>UALCAN: an update to the integrated cancer data analysis platform</article-title>. <source>Neoplasia</source>. <year>2022</year>; <volume>25</volume>:<fpage>18</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">35078134</pub-id></mixed-citation>
    </ref>
    <ref id="B3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cheng</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Chung</surname><given-names>I.F.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.Y.</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H.J.</given-names></string-name>, <string-name><surname>Fen</surname><given-names>J.J.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>W.C.</given-names></string-name>, <string-name><surname>Chang</surname><given-names>T.Y.</given-names></string-name>, <string-name><surname>Wong</surname><given-names>T.T.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H.W.</given-names></string-name></person-group><article-title>DriverDB: an exome sequencing database for cancer driver gene identification</article-title>. <source>Nucleic Acids Res.</source><year>2014</year>; <volume>42</volume>:<fpage>D1048</fpage>–<lpage>D1054</lpage>.<pub-id pub-id-type="pmid">24214964</pub-id></mixed-citation>
    </ref>
    <ref id="B4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>S.-H.</given-names></string-name>, <string-name><surname>Shen</surname><given-names>P.-C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>C.-Y.</given-names></string-name>, <string-name><surname>Hsu</surname><given-names>A.-N.</given-names></string-name>, <string-name><surname>Cho</surname><given-names>Y.-C.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>Y.-L.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>F.-H.</given-names></string-name>, <string-name><surname>Li</surname><given-names>C.-Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.-C.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>DriverDBv3: a multi-omics database for cancer driver gene research</article-title>. <source>Nucleic Acids Res.</source><year>2020</year>; <volume>48</volume>:<fpage>D863</fpage>–<lpage>D870</lpage>.<pub-id pub-id-type="pmid">31701128</pub-id></mixed-citation>
    </ref>
    <ref id="B5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinstein</surname><given-names>J.N.</given-names></string-name>, <string-name><surname>Collisson</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Mills</surname><given-names>G.B.</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>K.R.</given-names></string-name>, <string-name><surname>Ozenberger</surname><given-names>B.A.</given-names></string-name>, <string-name><surname>Ellrott</surname><given-names>K.</given-names></string-name>, <string-name><surname>Shmulevich</surname><given-names>I.</given-names></string-name>, <string-name><surname>Sander</surname><given-names>C.</given-names></string-name>, <string-name><surname>Stuart</surname><given-names>J.M.</given-names></string-name></person-group><article-title>The Cancer Genome Atlas Pan-Cancer analysis project</article-title>. <source>Nat. Genet.</source><year>2013</year>; <volume>45</volume>:<fpage>1113</fpage>–<lpage>1120</lpage>.<pub-id pub-id-type="pmid">24071849</pub-id></mixed-citation>
    </ref>
    <ref id="B6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hudson</surname><given-names>T.J.</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>W.</given-names></string-name>, <string-name><surname>Artez</surname><given-names>A.</given-names></string-name>, <string-name><surname>Barker</surname><given-names>A.D.</given-names></string-name>, <string-name><surname>Bell</surname><given-names>C.</given-names></string-name>, <string-name><surname>Bernabé</surname><given-names>R.R.</given-names></string-name>, <string-name><surname>Bhan</surname><given-names>M.K.</given-names></string-name>, <string-name><surname>Calvo</surname><given-names>F.</given-names></string-name>, <string-name><surname>Eerola</surname><given-names>I.</given-names></string-name>, <string-name><surname>Gerhard</surname><given-names>D.S.</given-names></string-name><etal>et al</etal>.</person-group><article-title>International network of cancer genome projects</article-title>. <source>Nature</source>. <year>2010</year>; <volume>464</volume>:<fpage>993</fpage>–<lpage>998</lpage>.<pub-id pub-id-type="pmid">20393554</pub-id></mixed-citation>
    </ref>
    <ref id="B7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname><given-names>X.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Alexandrov</surname><given-names>L.B.</given-names></string-name>, <string-name><surname>Edmonson</surname><given-names>M.N.</given-names></string-name>, <string-name><surname>Gawad</surname><given-names>C.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Rusch</surname><given-names>M.C.</given-names></string-name>, <string-name><surname>Easton</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours</article-title>. <source>Nature</source>. <year>2018</year>; <volume>555</volume>:<fpage>371</fpage>–<lpage>376</lpage>.<pub-id pub-id-type="pmid">29489755</pub-id></mixed-citation>
    </ref>
    <ref id="B8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Colaprico</surname><given-names>A.</given-names></string-name>, <string-name><surname>Silva</surname><given-names>T.C.</given-names></string-name>, <string-name><surname>Olsen</surname><given-names>C.</given-names></string-name>, <string-name><surname>Garofano</surname><given-names>L.</given-names></string-name>, <string-name><surname>Cava</surname><given-names>C.</given-names></string-name>, <string-name><surname>Garolini</surname><given-names>D.</given-names></string-name>, <string-name><surname>Sabedot</surname><given-names>T.S.</given-names></string-name>, <string-name><surname>Malta</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Pagnotta</surname><given-names>S.M.</given-names></string-name>, <string-name><surname>Castiglioni</surname><given-names>I.</given-names></string-name><etal>et al</etal>.</person-group><article-title>TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data</article-title>. <source>Nucleic Acids Res.</source><year>2016</year>; <volume>44</volume>:<fpage>e71</fpage>.<pub-id pub-id-type="pmid">26704973</pub-id></mixed-citation>
    </ref>
    <ref id="B9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saal</surname><given-names>L.H.</given-names></string-name>, <string-name><surname>Vallon-Christersson</surname><given-names>J.</given-names></string-name>, <string-name><surname>Häkkinen</surname><given-names>J.</given-names></string-name>, <string-name><surname>Hegardt</surname><given-names>C.</given-names></string-name>, <string-name><surname>Grabau</surname><given-names>D.</given-names></string-name>, <string-name><surname>Winter</surname><given-names>C.</given-names></string-name>, <string-name><surname>Brueffer</surname><given-names>C.</given-names></string-name>, <string-name><surname>Tang</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Reuterswärd</surname><given-names>C.</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine</article-title>. <source>Genome Med.</source><year>2015</year>; <volume>7</volume>:<fpage>20</fpage>.<pub-id pub-id-type="pmid">25722745</pub-id></mixed-citation>
    </ref>
    <ref id="B10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akbani</surname><given-names>R.</given-names></string-name>, <string-name><surname>Ng</surname><given-names>P.K.S.</given-names></string-name>, <string-name><surname>Werner</surname><given-names>H.M.J.</given-names></string-name>, <string-name><surname>Shahmoradgoli</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Ju</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>W.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>J.-Y.</given-names></string-name>, <string-name><surname>Yoshihara</surname><given-names>K.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name><etal>et al</etal>.</person-group><article-title>A pan-cancer proteomic perspective on The Cancer Genome Atlas</article-title>. <source>Nat. Commun.</source><year>2014</year>; <volume>5</volume>:<fpage>3887</fpage>.<pub-id pub-id-type="pmid">24871328</pub-id></mixed-citation>
    </ref>
    <ref id="B11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leiserson</surname><given-names>M.D.M.</given-names></string-name>, <string-name><surname>Wu</surname><given-names>H.-T.</given-names></string-name>, <string-name><surname>Vandin</surname><given-names>F.</given-names></string-name>, <string-name><surname>Raphael</surname><given-names>B.J.</given-names></string-name></person-group><article-title>CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer</article-title>. <source>Genome Biol.</source><year>2015</year>; <volume>16</volume>:<fpage>160</fpage>.<pub-id pub-id-type="pmid">26253137</pub-id></mixed-citation>
    </ref>
    <ref id="B12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hou</surname><given-names>J.P.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J.</given-names></string-name></person-group><article-title>DawnRank: discovering personalized driver genes in cancer</article-title>. <source>Genome Medicine</source>. <year>2014</year>; <volume>6</volume>:<fpage>56</fpage>.<pub-id pub-id-type="pmid">25177370</pub-id></mixed-citation>
    </ref>
    <ref id="B13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Argelaguet</surname><given-names>R.</given-names></string-name>, <string-name><surname>Arnol</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bredikhin</surname><given-names>D.</given-names></string-name>, <string-name><surname>Deloro</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Velten</surname><given-names>B.</given-names></string-name>, <string-name><surname>Marioni</surname><given-names>J.C.</given-names></string-name>, <string-name><surname>Stegle</surname><given-names>O.</given-names></string-name></person-group><article-title>MOFA+: a statistical framework for comprehensive integration of multi-modal single-cell data</article-title>. <source>Genome Biol.</source><year>2020</year>; <volume>21</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">32393329</pub-id></mixed-citation>
    </ref>
    <ref id="B14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname><given-names>A.</given-names></string-name>, <string-name><surname>Shannon</surname><given-names>C.P.</given-names></string-name>, <string-name><surname>Gautier</surname><given-names>B.</given-names></string-name>, <string-name><surname>Rohart</surname><given-names>F.</given-names></string-name>, <string-name><surname>Vacher</surname><given-names>M.</given-names></string-name>, <string-name><surname>Tebbutt</surname><given-names>S.J.</given-names></string-name>, <string-name><surname>Lê Cao</surname><given-names>K.-A.</given-names></string-name></person-group><article-title>DIABLO: an integrative approach for identifying key molecular drivers from multi-omics assays</article-title>. <source>Bioinformatics</source>. <year>2019</year>; <volume>35</volume>:<fpage>3055</fpage>–<lpage>3062</lpage>.<pub-id pub-id-type="pmid">30657866</pub-id></mixed-citation>
    </ref>
    <ref id="B15">
      <label>15.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhang</surname><given-names>D.</given-names></string-name>, <string-name><surname>Bin</surname><given-names>Y.</given-names></string-name></person-group><article-title>DriverSubNet: a novel algorithm for identifying cancer driver genes by subnetwork enrichment analysis</article-title>. <source>Front. Genet.</source><year>2021</year>; <volume>11</volume>:<fpage>607798</fpage>.<pub-id pub-id-type="pmid">33679866</pub-id></mixed-citation>
    </ref>
    <ref id="B16">
      <label>16.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thévenot</surname><given-names>E.A.</given-names></string-name>, <string-name><surname>Roux</surname><given-names>A.</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Ezan</surname><given-names>E.</given-names></string-name>, <string-name><surname>Junot</surname><given-names>C.</given-names></string-name></person-group><article-title>Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and OPLS statistical analyses</article-title>. <source>J. Proteome Res.</source><year>2015</year>; <volume>14</volume>:<fpage>3322</fpage>–<lpage>3335</lpage>.<pub-id pub-id-type="pmid">26088811</pub-id></mixed-citation>
    </ref>
    <ref id="B17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Moon</surname><given-names>S.</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>H.</given-names></string-name></person-group><article-title>SDGCCA: supervised deep generalized canonical correlation analysis for multi-omics integration</article-title>. <source>J. Comput. Biol.</source><year>2022</year>; <volume>29</volume>:<fpage>892</fpage>–<lpage>907</lpage>.<pub-id pub-id-type="pmid">35951002</pub-id></mixed-citation>
    </ref>
    <ref id="B18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tenenhaus</surname><given-names>A.</given-names></string-name>, <string-name><surname>Philippe</surname><given-names>C.</given-names></string-name>, <string-name><surname>Guillemot</surname><given-names>V.</given-names></string-name>, <string-name><surname>Le Cao</surname><given-names>K.-A.</given-names></string-name>, <string-name><surname>Grill</surname><given-names>J.</given-names></string-name>, <string-name><surname>Frouin</surname><given-names>V.</given-names></string-name></person-group><article-title>Variable selection for generalized canonical correlation analysis</article-title>. <source>Biostatistics</source>. <year>2014</year>; <volume>15</volume>:<fpage>569</fpage>–<lpage>583</lpage>.<pub-id pub-id-type="pmid">24550197</pub-id></mixed-citation>
    </ref>
    <ref id="B19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Djuric</surname><given-names>U.</given-names></string-name>, <string-name><surname>Lam</surname><given-names>K.H.B.</given-names></string-name>, <string-name><surname>Kao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Batruch</surname><given-names>I.</given-names></string-name>, <string-name><surname>Jevtic</surname><given-names>S.</given-names></string-name>, <string-name><surname>Papaioannou</surname><given-names>M.D.</given-names></string-name>, <string-name><surname>Diamandis</surname><given-names>P.</given-names></string-name></person-group><article-title>Defining protein pattern differences among molecular subtypes of diffuse gliomas using mass spectrometry</article-title>. <source>Mol. Cell. Proteomics</source>. <year>2019</year>; <volume>18</volume>:<fpage>2029</fpage>–<lpage>2043</lpage>.<pub-id pub-id-type="pmid">31353322</pub-id></mixed-citation>
    </ref>
    <ref id="B20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Butti</surname><given-names>R.</given-names></string-name>, <string-name><surname>Das</surname><given-names>S.</given-names></string-name>, <string-name><surname>Gunasekaran</surname><given-names>V.P.</given-names></string-name>, <string-name><surname>Yadav</surname><given-names>A.S.</given-names></string-name>, <string-name><surname>Kumar</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kundu</surname><given-names>G.C.</given-names></string-name></person-group><article-title>Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges</article-title>. <source>Mol. Cancer</source>. <year>2018</year>; <volume>17</volume>:<fpage>34</fpage>.<pub-id pub-id-type="pmid">29455658</pub-id></mixed-citation>
    </ref>
    <ref id="B21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>M.</given-names></string-name>, <string-name><surname>Dorsey</surname><given-names>T.H.</given-names></string-name>, <string-name><surname>Prieto</surname><given-names>D.A.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X.W.</given-names></string-name>, <string-name><surname>Ruppin</surname><given-names>E.</given-names></string-name>, <string-name><surname>Veenstra</surname><given-names>T.D.</given-names></string-name>, <string-name><surname>Ambs</surname><given-names>S.</given-names></string-name></person-group><article-title>Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival</article-title>. <source>Genome Medicine</source>. <year>2018</year>; <volume>10</volume>:<fpage>94</fpage>.<pub-id pub-id-type="pmid">30501643</pub-id></mixed-citation>
    </ref>
    <ref id="B22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>ten Hoorn</surname><given-names>S.</given-names></string-name>, <string-name><surname>de Back</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Sommeijer</surname><given-names>D.W.</given-names></string-name>, <string-name><surname>Vermeulen</surname><given-names>L.</given-names></string-name></person-group><article-title>Clinical value of consensus molecular subtypes in colorectal cancer: a systematic review and meta analysis</article-title>. <source>J. Natl. Cancer Inst.</source><year>2021</year>; <volume>114</volume>:<fpage>503</fpage>–<lpage>516</lpage>.</mixed-citation>
    </ref>
    <ref id="B23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Qin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Yi</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Gao</surname><given-names>H.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>F.</given-names></string-name>, <string-name><surname>Guan</surname><given-names>M.</given-names></string-name></person-group><article-title>Delving into the heterogeneity of different breast cancer subtypes and the prognostic models utilizing scRNA-Seq and bulk RNA-Seq</article-title>. <source>Int. J. Mol. Sci.</source><year>2022</year>; <volume>23</volume>:<fpage>9936</fpage>.<pub-id pub-id-type="pmid">36077333</pub-id></mixed-citation>
    </ref>
    <ref id="B24">
      <label>24.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>S.</given-names></string-name>, <string-name><surname>Xie</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Cai</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H.</given-names></string-name>, <string-name><surname>He</surname><given-names>M.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L.</given-names></string-name>, <string-name><surname>Liao</surname><given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ren</surname><given-names>X.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Multiomic analysis reveals comprehensive tumor heterogeneity and distinct immune subtypes in multifocal intrahepatic cholangiocarcinoma</article-title>. <source>Clin. Cancer Res.</source><year>2022</year>; <volume>28</volume>:<fpage>1896</fpage>–<lpage>1910</lpage>.<pub-id pub-id-type="pmid">34526363</pub-id></mixed-citation>
    </ref>
    <ref id="B25">
      <label>25.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Leonard</surname><given-names>M.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>D.</given-names></string-name>, <string-name><surname>Mahmoud</surname><given-names>C.</given-names></string-name>, <string-name><surname>Khan</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>Lower</surname><given-names>E.E.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X.</given-names></string-name></person-group><article-title>HER2-driven breast tumorigenesis relies upon interactions of the estrogen receptor with coactivator MED1</article-title>. <source>Cancer Res.</source><year>2018</year>; <volume>78</volume>:<fpage>422</fpage>–<lpage>435</lpage>.<pub-id pub-id-type="pmid">29187405</pub-id></mixed-citation>
    </ref>
    <ref id="B26">
      <label>26.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gui</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>P.</given-names></string-name></person-group><article-title>Overexpressing PTTG family genes predict poor prognosis in kidney renal clear cell carcinoma</article-title>. <source>World J. Surg. Oncol.</source><year>2021</year>; <volume>19</volume>:<fpage>111</fpage>.<pub-id pub-id-type="pmid">33845847</pub-id></mixed-citation>
    </ref>
    <ref id="B27">
      <label>27.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yang</surname><given-names>L.</given-names></string-name>, <string-name><surname>Yao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Kuang</surname><given-names>X.Y.</given-names></string-name>, <string-name><surname>Zuo</surname><given-names>W.J.</given-names></string-name>, <string-name><surname>Li</surname><given-names>S.</given-names></string-name>, <string-name><surname>Qiao</surname><given-names>F.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y.R.</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Z.G.</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>S.L.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients</article-title>. <source>Nat. Commun.</source><year>2018</year>; <volume>9</volume>:<fpage>1357</fpage>.<pub-id pub-id-type="pmid">29636477</pub-id></mixed-citation>
    </ref>
    <ref id="B28">
      <label>28.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kołodziej</surname><given-names>P.</given-names></string-name>, <string-name><surname>Nicoś</surname><given-names>M.</given-names></string-name>, <string-name><surname>Krawczyk</surname><given-names>P.A.</given-names></string-name>, <string-name><surname>Bogucki</surname><given-names>J.</given-names></string-name>, <string-name><surname>Karczmarczyk</surname><given-names>A.</given-names></string-name>, <string-name><surname>Zalewski</surname><given-names>D.</given-names></string-name>, <string-name><surname>Kubrak</surname><given-names>T.</given-names></string-name>, <string-name><surname>Kołodziej</surname><given-names>E.</given-names></string-name>, <string-name><surname>Makuch-Kocka</surname><given-names>A.</given-names></string-name>, <string-name><surname>Madej-Czerwonka</surname><given-names>B.</given-names></string-name><etal>et al</etal>.</person-group><article-title>The correlation of mutations and expressions of genes within the PI3K/Akt/mTOR pathway in breast cancer - a preliminary study</article-title>. <source>Int. J. Mol. Sci.</source><year>2021</year>; <volume>22</volume>:<fpage>2061</fpage>.<pub-id pub-id-type="pmid">33669698</pub-id></mixed-citation>
    </ref>
    <ref id="B29">
      <label>29.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cizkova</surname><given-names>M.</given-names></string-name>, <string-name><surname>Vacher</surname><given-names>S.</given-names></string-name>, <string-name><surname>Meseure</surname><given-names>D.</given-names></string-name>, <string-name><surname>Trassard</surname><given-names>M.</given-names></string-name>, <string-name><surname>Susini</surname><given-names>A.</given-names></string-name>, <string-name><surname>Mlcuchova</surname><given-names>D.</given-names></string-name>, <string-name><surname>Callens</surname><given-names>C.</given-names></string-name>, <string-name><surname>Rouleau</surname><given-names>E.</given-names></string-name>, <string-name><surname>Spyratos</surname><given-names>F.</given-names></string-name>, <string-name><surname>Lidereau</surname><given-names>R.</given-names></string-name><etal>et al</etal>.</person-group><article-title>PIK3R1 underexpression is an independent prognostic marker in breast cancer</article-title>. <source>BMC Cancer</source>. <year>2013</year>; <volume>13</volume>:<fpage>545</fpage>.<pub-id pub-id-type="pmid">24229379</pub-id></mixed-citation>
    </ref>
    <ref id="B30">
      <label>30.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shenoy</surname><given-names>S.</given-names></string-name></person-group><article-title>CDH1 (E-Cadherin) mutation and gastric cancer: genetics, molecular mechanisms and guidelines for management</article-title>. <source>Cancer Manag. Res.</source><year>2019</year>; <volume>11</volume>:<fpage>10477</fpage>–<lpage>10486</lpage>.<pub-id pub-id-type="pmid">31853199</pub-id></mixed-citation>
    </ref>
    <ref id="B31">
      <label>31.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname><given-names>T.</given-names></string-name>, <string-name><surname>Xue</surname><given-names>L.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>B.</given-names></string-name>, <string-name><surname>He</surname><given-names>H.</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>W.</given-names></string-name>, <string-name><surname>Hao</surname><given-names>L.</given-names></string-name>, <string-name><surname>Ma</surname><given-names>W.</given-names></string-name>, <string-name><surname>Zang</surname><given-names>G.</given-names></string-name>, <string-name><surname>Han</surname><given-names>C.</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y.</given-names></string-name></person-group><article-title>CDH1 overexpression predicts bladder cancer from early stage and inversely correlates with immune infiltration</article-title>. <source>BMC Urol.</source><year>2022</year>; <volume>22</volume>:<fpage>156</fpage>.<pub-id pub-id-type="pmid">36131343</pub-id></mixed-citation>
    </ref>
    <ref id="B32">
      <label>32.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pomo</surname><given-names>J.M.</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>R.M.</given-names></string-name>, <string-name><surname>Gullapalli</surname><given-names>R.R.</given-names></string-name></person-group><article-title>Influence of TP53 and CDH1 genes in hepatocellular cancer spheroid formation and culture: a model system to understand cancer cell growth mechanics</article-title>. <source>Cancer Cell Int.</source><year>2016</year>; <volume>16</volume>:<fpage>44</fpage>.<pub-id pub-id-type="pmid">27303212</pub-id></mixed-citation>
    </ref>
    <ref id="B33">
      <label>33.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Richards</surname><given-names>F.M.</given-names></string-name>, <string-name><surname>McKee</surname><given-names>S.A.</given-names></string-name>, <string-name><surname>Rajpar</surname><given-names>M.H.</given-names></string-name>, <string-name><surname>Cole</surname><given-names>T.R.</given-names></string-name>, <string-name><surname>Evans</surname><given-names>D.G.</given-names></string-name>, <string-name><surname>Jankowski</surname><given-names>J.A.</given-names></string-name>, <string-name><surname>McKeown</surname><given-names>C.</given-names></string-name>, <string-name><surname>Sanders</surname><given-names>D.S.</given-names></string-name>, <string-name><surname>Maher</surname><given-names>E.R.</given-names></string-name></person-group><article-title>Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer</article-title>. <source>Hum. Mol. Genet.</source><year>1999</year>; <volume>8</volume>:<fpage>607</fpage>–<lpage>610</lpage>.<pub-id pub-id-type="pmid">10072428</pub-id></mixed-citation>
    </ref>
    <ref id="B34">
      <label>34.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xie</surname><given-names>D.</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Wan</surname><given-names>X.</given-names></string-name>, <string-name><surname>Li</surname><given-names>J.</given-names></string-name>, <string-name><surname>Pei</surname><given-names>Q.</given-names></string-name>, <string-name><surname>Luo</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J.</given-names></string-name>, <string-name><surname>Ye</surname><given-names>T.</given-names></string-name></person-group><article-title>The potential role of CDH1 as an oncogene combined with related miRNAs and their diagnostic value in breast cancer</article-title>. <source>Front. Endocrinol. (Lausanne)</source>. <year>2022</year>; <volume>13</volume>:<fpage>916469</fpage>.<pub-id pub-id-type="pmid">35784532</pub-id></mixed-citation>
    </ref>
    <ref id="B35">
      <label>35.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname><given-names>Y.</given-names></string-name>, <string-name><surname>Beyer</surname><given-names>A.</given-names></string-name>, <string-name><surname>Aebersold</surname><given-names>R.</given-names></string-name></person-group><article-title>On the dependency of cellular protein levels on mRNA abundance</article-title>. <source>Cell</source>. <year>2016</year>; <volume>165</volume>:<fpage>535</fpage>–<lpage>550</lpage>.<pub-id pub-id-type="pmid">27104977</pub-id></mixed-citation>
    </ref>
    <ref id="B36">
      <label>36.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andrieux</surname><given-names>G.</given-names></string-name>, <string-name><surname>Chakraborty</surname><given-names>S.</given-names></string-name>, <string-name><surname>Das</surname><given-names>T.</given-names></string-name>, <string-name><surname>Boerries</surname><given-names>M.</given-names></string-name></person-group><article-title>Alteration of proteotranscriptomic landscape reveals the transcriptional regulatory circuits controlling key-signaling pathways and metabolic reprogramming during tumor evolution</article-title>. <source>Front. Cell Dev. Biol.</source><year>2020</year>; <volume>8</volume>:<fpage>586479</fpage>.<pub-id pub-id-type="pmid">33384992</pub-id></mixed-citation>
    </ref>
    <ref id="B37">
      <label>37.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname><given-names>F.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z.</given-names></string-name>, <string-name><surname>Duan</surname><given-names>J.</given-names></string-name>, <string-name><surname>An</surname><given-names>T.</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J.</given-names></string-name>, <string-name><surname>Bai</surname><given-names>H.</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J.</given-names></string-name>, <string-name><surname>the Key Laboratory of</surname><given-names>C.</given-names></string-name>, <string-name><surname>Translational</surname><given-names>R.</given-names></string-name></person-group><article-title>Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR</article-title>. <source>J. Exp. Clin. Cancer Res.</source><year>2012</year>; <volume>31</volume>:<fpage>65</fpage>.<pub-id pub-id-type="pmid">22901364</pub-id></mixed-citation>
    </ref>
    <ref id="B38">
      <label>38.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sette</surname><given-names>G.</given-names></string-name>, <string-name><surname>Salvati</surname><given-names>V.</given-names></string-name>, <string-name><surname>Mottolese</surname><given-names>M.</given-names></string-name>, <string-name><surname>Visca</surname><given-names>P.</given-names></string-name>, <string-name><surname>Gallo</surname><given-names>E.</given-names></string-name>, <string-name><surname>Fecchi</surname><given-names>K.</given-names></string-name>, <string-name><surname>Pilozzi</surname><given-names>E.</given-names></string-name>, <string-name><surname>Duranti</surname><given-names>E.</given-names></string-name>, <string-name><surname>Policicchio</surname><given-names>E.</given-names></string-name>, <string-name><surname>Tartaglia</surname><given-names>M.</given-names></string-name><etal>et al</etal>.</person-group><article-title>Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer</article-title>. <source>Cell Death. Dis.</source><year>2015</year>; <volume>6</volume>:<fpage>e1850</fpage>.<pub-id pub-id-type="pmid">26247735</pub-id></mixed-citation>
    </ref>
    <ref id="B39">
      <label>39.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zimmer</surname><given-names>S.</given-names></string-name>, <string-name><surname>Kahl</surname><given-names>P.</given-names></string-name>, <string-name><surname>Buhl</surname><given-names>T.M.</given-names></string-name>, <string-name><surname>Steiner</surname><given-names>S.</given-names></string-name>, <string-name><surname>Wardelmann</surname><given-names>E.</given-names></string-name>, <string-name><surname>Merkelbach-Bruse</surname><given-names>S.</given-names></string-name>, <string-name><surname>Buettner</surname><given-names>R.</given-names></string-name>, <string-name><surname>Heukamp</surname><given-names>L.C.</given-names></string-name></person-group><article-title>Epidermal growth factor receptor mutations in non-small cell lung cancer influence downstream Akt, MAPK and Stat3 signaling</article-title>. <source>J. Cancer Res. Clin. Oncol.</source><year>2009</year>; <volume>135</volume>:<fpage>723</fpage>–<lpage>730</lpage>.<pub-id pub-id-type="pmid">19002495</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
